DRUGS related term(s) Crime; Pharmaceuticals

Addresses

State of the Union: President Trump, S862–S866 [5FE], H1356–H1361 [5FE]

Amendments

Dept. of HHS: establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10041 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H10167, H10202, H10204, H10205, H10207, H10208, H10210, H10211, H10214, H10215, H10216, H10217 [12DE]

Health: extend certain public health programs (H.R. 4378), S5712 [25SE], S5722, S5758 [26SE]

——— extend certain public health programs (H.R. 4378), consideration (H. Res. 564), H7785 [19SE]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3873, H3874, H3876, H3877, H3878, H3879, H3880, H3882, H3883, H3884, H3885, H3886, H3887, H3888, H3889, H3891, H3892, H3893, H3894, H3896, H3897, H3898, H3900, H3901 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3811 [15MY]

Trump, President: terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), S1910 [14MR]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), consideration (H. Res. 144), H2119 [26FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), consideration (H. Res. 591), H8005 [26SE]

Analyses

Lower Drug Costs Now Act (H.R. 3), E1572 [10DE]

Appointments

Senate Caucus on International Narcotics Control, S146 [10JA], S279 [16JA]

Articles and editorials

Foreign Cartels Embrace Home-Grown Marijuana in Pot-Legal States, H7966 [25SE]

I Support Trump’s Vision on Border Security. But I Would Vote Against the Emergency, S1860 [14MR]

Is Marijuana as Safe as We Think?, H7967–H7969 [25SE]

It’s Time for Republicans in Congress To Put Country Over Party, S1860 [14MR]

Pentagon Has Warned of Dire Outcomes if Military Projects Canceled for Wall Don’t Happen, S5655 [24SE]

Price Controls Would Stifle Biotech Innovation, H10132 [12DE]

Role of the Military in Combating Human Trafficking—A South African Perspective, H4712 [18JN]

Russian Doping Chief Says Thousands of Drug Tests Were Manipulated, H8340 [22OC]

Trump vs. Congress—The Emergency Declaration Should Not Be Resolved in Court, S1613 [4MR]

Trump’s Emergency Exit—How He Can Declare Victory on Wall Money Without Losing a Vote, S1859 [14MR]

U.S. Lawmakers Seek To Criminalize Doping in Global Competitions, H8341 [22OC]

U.S. Special Operations Command’s Heros Combat Human Trafficking, H4711 [18JN]

Bills and resolutions

Abortion: ensure that a woman seeking a chemical abortion is informed that it may be possible to reverse the intended effects of the abortion if the woman changes her mind (see H.R. 2010), H2938 [1AP]

——— prohibit chemical abortions performed without the presence of a health care provider (see H.R. 4935), H8678 [30OC]

Advertising: require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising (see H.R. 3327), H4771 [18JN]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug (see H. Con. Res. 55), H7377 [24JY]

Bureau of Prisons: improve treatment of Federal prisoners who are primary caretaker parents (see S. 992), S2189 [2AP] (see H.R. 2034), H2985 [2AP]

Capitol Building and Grounds: authorize use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event (see S. Res. 158), S2387 [10AP]

——— authorize use of Philip A. Hart Senate Office Building atrium for DEA National Prescription Drug Take Back Day (see S. Res. 359), S5841 [16OC]

CDC: provide for national campaign to raise awarenesss of the importance, and combat misinformation about, vaccines in order to increase vaccination rates (see S. 1619), S3059 [22MY]

——— provide for national system for surveillance of vaccine rates, authorize research on vaccine hesitancy, and increase public understanding of the benefits of immunizations (see H.R. 2862), H4063 [21MY]

Centers for Medicare & Medicaid Services: conduct study on antipsychotic prescribing practices in nonnursing home settings (see H.R. 1955), H2915 [28MR]

——— ensure home infusion therapy services are accessible to all Medicare beneficiaries regardless of the presence of a skilled professional (see H. Con. Res. 63), H7773 [18SE]

Central America: implement U.S. Strategy for Engagement in Central America, support people and governments, and address root causes of migration from El Salvador, Guatemala, and Honduras (see H. Res. 426), H4313 [4JN]

——— redirect foreign assistance provided to El Salvador, Guatemala, and Honduras and target it to fight systemic corruption and address driving causes of illegal immigration into the U.S. (see H. Res. 18), H211 [3JA]

——— support people and strengthen U.S. national security by addressing root causes of migration from El Salvador, Guatemala, and Honduras (see H.R. 2615), H3678 [9MY] (see H.R. 3524), H5255 [27JN]

Coast Guard: enhance land-based unmanned aircraft system program and maritime patrol aircraft to help identify and interdict illicit drugs (see S. 2173), S4948 [18JY]

——— study and report on interdiction of illicit drugs in the transit zones (see S. 2152), S4907 [17JY]

Colleges and universities: designate institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing (see H.R. 4866), H8538 [28OC]

Computers: establish an interactive dashboard to allow the public to review information on price and utilization of prescription drugs purchased by Federal programs (see S. 709), S1733 [7MR]

Consumers: allow State-based, market-oriented, prescription drug negotiations to lower drug prices, encourage competition, and increase consumer choice and access (see H.R. 2038), H2986 [2AP]

——— lower cost of prescription drugs (see H.R. 3947), H7377 [24JY]

——— lower out of pocket spending, protect access to new cures and medications, strengthen transparency, and encourage competition (see S. 3129), S7208 [19DE] (see H.R. 19), H9386 [9DE]

——— reform prescription drug pricing and reduce out-of-pocket costs by ensuring consumers benefit from negotiated rebates by requiring coinsurance obligations be set as a percentage of a drug’s net price not list price (see S. 1384), S2769 [9MY] (see H.R. 3805), H5998 [17JY]

——— require National Academy of Medicine study on determining reasonable drug prices and establish Drug Affordability and Access Committee to issue reasonable pricing determination for each drug (see S. 2387), S5248 [31JY]

——— require reporting on prescription drug expenditures under group health plans and on prescription drug price changes (see S. 1664), S3105 [23MY] (see H.R. 5239), H9168 [21NO]

Contraceptives: establish certain duties for pharmacies to ensure provision of FDA-approved contraception (see S. 1086), S2328 [9AP] (see H.R. 2182), H3217 [9AP]

——— provide women greater access by increasing availability of contraceptives over-the-counter and allowing use of health savings accounts to purchase such products (see S. 930), S2087 [28MR]

Courts: increase mandatory minimum sentencing penalties for drug traffickers and dealers convicted for distribution of fentanyl (see S. 1724), S3250 [5JN]

Crime: clarify that using drugs to cause a person to engage in a commercial sex act constitutes coercion and using drugs to provide or obtain the labor or services of a person constitutes forced labor (see S. 2197), S4966 [22JY]

——— define term ‘‘serious felony’’ to allow prosecutors to seek enhanced penalties against violent, repeat offenders (see S. 1547), S2962 [20MY] (see H.R. 2837), H4009 [20MY]

——— prohibit knowing possession of a pill press mold with intent to manufacture a counterfeit substance in schedule I or II in a capsule, tablet, and other form intended for distribution (see S. 2573), S5748 [26SE] (see H.R. 4510), H8053 [26SE]

——— require automatic sealing of certain minor nonviolent criminal records (see H.R. 2348), H3279 [22AP]

——— seal or expunge nonviolent criminal records, reform treatment of juveniles in the justice system, and lift ban on certain Federal benefits for low-level drug offenders (see H.R. 2410), H3339 [30AP]

——— seal records for Federal nonviolent criminal offenses related to substance use disorders (see S. 423), S1133 [7FE]

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (see S. 2244), S5062 [24JY] (see H.R. 4131), H7481 [30JY]

——— amend certain regulations so that practitioners may not administer more than 3 days of medication to a person at one time when administering narcotics in order to relieve acute withdrawal symptoms (see H.R. 2281), H3255 [10AP]

——— authorize debarment of certain controlled substances registrants (see H.R. 4806), H8455 [23OC]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (see H.R. 4563), H8080 [27SE]

——— clarify how controlled substance analogues that are imported or offered for import are to be regulated (see S. 2764), S6333 [31OC] (see H.R. 4963), H8718 [31OC]

——— clarify process for registrants to exercise due diligence upon discovering a suspicious order (see H.R. 3878), H7239 [23JY]

——— convene a task force to recommend the most effective program to share data and implement real-time drug diversion prevention (see S. 2686), S6092 [23OC] (see H.R. 4814), H8455 [23OC]

——— deem drugs or other substances that act as mu opioid receptor agonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 2580), H3500 [8MY]

——— eliminate separate registration requirement for dispensing narcotic drugs categorized in schedules with lower potential for abuse that are intended for maintenance or detoxification treatment (see S. 2074), S4773 [10JY] (see H.R. 2482), H3439 [2MY]

——— extend temporary scheduling order listing fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5233), H9168 [21NO]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see S. 1622), S3059 [22MY] (see S. 2701), S6155 [24OC] (see S. 3148), S7208 [19DE] (see H.R. 2935), H4119 [22MY] (see H.R. 5421), H10257 [12DE]

——— provide for modification, transfer, and termination of a registration to manufacture, distribute, or dispense controlled substances or list I chemicals (see H.R. 4812), H8455 [23OC]

——— provide information on best practices and strategies for responding in the event of a robbery of a pharmacy (see H.R. 4505), H8052 [26SE]

——— regulate selective androgen receptor modulators in the same manner as anabolic steroids (see S. 2895), S6669 [19NO]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 3070), S7113 [17DE]

——— require health care professionals to certify they will not prescribe more than a seven-day supply of opioids as treatment for acute pain or provide refills as part of their registration to prescribe opioids (see S. 724), S1734 [7MR] (see H.R. 1614), H2583 [7MR]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 424), S1133 [7FE]

Death and dying: ensure individuals facing the end of their lives have access to quality medical, palliative, and hospice care and oppose Federal policies or practices that support or facilitate assisted suicide (see H. Con. Res. 79), H10258 [12DE]

Dept. of Agriculture: improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (see H.R. 5249), H9169 [21NO]

Dept. of Defense: develop a strategy to recruit and retain mental health providers and direct military departments to develop medication monitoring programs (see H.R. 1801), H2745 [14MR]

——— include in each national defense strategy steps to strengthen the U.S. industrial base and to assure an uninterrupted supply of medicines (see H.R. 4710), H8226 [17OC]

Dept. of Education: allow students convicted of marijuana possession to retain financial aid eligibility if they complete a drug rehabilitation program (see H.R. 4089), H7476 [26JY]

——— establish State-Federal partnerships to provide students with debt-free college, provide Pell Grant eligibility to certain immigrants, and restore assistance eligibility for drug-related offenses (see S. 672), S1705 [6MR] (see H.R. 1571), H2504 [6MR]

——— provide grants for institutions of higher education to prevent substance misuse (see S. 1281), S2612 [2MY] (see H.R. 3591), H5258 [27JN]

——— repeal suspension of eligibility for Federal grants, student loans, and work assistance for drug-related offenses (see H.R. 4584), H8088 [1OC]

——— study student mental health at institutions of higher education and issue guidance on compliance with Americans With Disabilities Act for mental health and substance use disorder policies (see H.R. 5204), H9121 [20NO]

Dept. of HHS: add a new set of measures to Medicare Advantage program 5-star rating system in order to encourage increased access to biosimilar biological products (see H.R. 4629), H8101 [8OC]

——— address opioid drug abuse epidemic (see H.R. 2922), H4118 [22MY]

——— administer vaccinations for hepatitis A, at no cost to the inoculated, in certain areas at risk of a hepatitis A outbreak (see H.R. 2361), H3283 [25AP]

——— allow expedited approval of generic prescription drugs and temporary importation of prescription drugs during noncompetitive drug markets and drug shortages (see S. 844), S1899 [14MR]

——— allow importation by wholesalers, pharmacies, and individuals of safe and affordable drugs from FDA-certified foreign sellers (see S. 97), S142 [10JA] (see H.R. 447), H462 [10JA]

——— allow personal importation of safe and affordable drugs from approved pharmacies in Canada (see S. 61), S103 [9JA] (see H.R. 478), H463 [10JA]

——— approve cheaper generic versions of certain drugs if pharmaceutical manufacturers refuse to lower drug prices down to the median price at which the drugs are available in other countries (see S. 102), S142 [10JA] (see H.R. 465), H462 [10JA]

——— authorize State Opioid Response Grants and Tribal Opioid Response Grants programs (see H.R. 2466), H3404 [1MY]

——— authorize State Opioid Response Grants program and allow use of funding to address methamphetamine and cocaine abuse (see S. 1925), S4168 [20JN] (see H.R. 4111), H7480 [30JY]

——— carry out a program to address health crisis of insufficient vaccinations (see H.R. 3058), H4215 [3JN]

——— condition receipt by State and local entities of preventive health services grants on establishment of vaccination requirements for public school students in accordance with certain CDC recommendations (see H.R. 2527), H3447 [3MY]

——— conduct a study on impact of affordability of insulin on insulin-dependent individuals (see S. 2855), S6604 [14NO]

——— conduct study on unintended impacts of sex trafficking legislation and loss of online services and platforms on the health and safety of sex workers (see H.R. 5448), H10608 [17DE]

——— educate health care professionals and the public on biosimilar biological products (see S. 1681), S3106 [23MY] (see H.R. 4400), H7834 [19SE]

——— eliminate percentage cap on funding under National Family Caregiver Support Program for older caregivers taking over primary caregiver role for a grandchild due to opioid epidemic (see H.R. 4853), H8457 [23OC]

——— enhance efforts to address antibiotic resistance (see S. 2304), S5141 [29JY]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see S. 1012), S2240 [3AP] (see H.R. 2062), H3067 [3AP]

——— ensure medications are affordable through increasing transparency, allowing Medicare to negotiate lower prices and importation of certain drugs, spurring innovation, and protecting competition (see S. 1801), S3363 [12JN]

——— enter into arrangement with National Academy of Sciences to conduct and update biennially study on effects of State legalized marijuana programs (see H.R. 1587), H2581 [7MR]

——— establish an annual reference price for insulin products for purposes of Federal health programs (see S. 2817), S6475 [7NO] (see H.R. 5364), H9386 [9DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (see H. Res. 758), H10015 [10DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (see H.R. 3), H7834 [19SE]

——— establish grant program to provide supportive services in permanent supportive housing for chronically homeless individuals who have physical or mental health conditions or substance use disorders (see H.R. 3272), H4694 [13JN]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in the prescription drug market (see H.R. 5501), H12289 [19DE]

——— establish Prescription Safety Alert System to combat prescription drug abuse by collecting, maintaining, and providing to dispensers patients’ prescription and dispensing history (see H.R. 1845), H2761 [21MR]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 1987), S4566 [26JN] (see H.R. 3523), H5201 [26JN]

——— establish requirements relative to prescription drug benefits (see S. 657), S1659 [5MR]

——— establish State insulin assistance programs, hold manufacturers accountable for excessive insulin price increases, and promote market competition to drive down prices (see S. 2004), S4628 [27JN] (see H.R. 4010), H7464 [25JY]

——— extend floor on area wage index under inpatient prospective payment system and provide eligibility for discounted drug prices under 340B drug pricing program to certain sole community hospitals (see H.R. 1323), H2046 [22FE]

——— impose a fee on opioid manufacturers to fund an increase in drug addiction treatment capacity (see S. 1662), S3105 [23MY] (see H.R. 3105), H4341 [5JN]

——— improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 1926), S4168 [20JN] (see H.R. 3815), H5999 [17JY]

——— incentivize low-cost drug options and generic competition and extend funding for community health centers, National Health Service Corps, teaching health centers and other public health programs (see H.R. 2700), H3788 [14MY]

——— increase maximum number of special masters allowed in U.S. Court of Federal Claims to hear cases under National Vaccine Injury Compensation Program (see S. 1638), S3104 [23MY] (see H.R. 3003), H4163 [23MY]

——— limit orphan drug exclusion under the discount drug program requiring drug manufacturers to provide drugs to eligible health care organizations at reduced prices (see H.R. 4538), H8054 [26SE]

——— make opioid treatment programs eligible for grants under Health Profession Opportunity Grant program (see H.R. 3341), H4917 [19JN]

——— mitigate drug shortages by prioritizing review of new drug applications, inspections, and reasons for shortages and assess national security threats associated with drug and ingredient shortages (see S. 2723), S6242 [29OC]

——— negotiate prices of prescription drugs furnished under Medicare part D and mandate production of generic versions of drugs if pharmaceutical companies fail to negotiate in good faith (see S. 377), S1131 [7FE] (see H.R. 1046), H1458 [7FE]

——— prohibit from treating any Medicaid-related funds recovered from pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment (see H.R. 5242), H9168 [21NO]

——— prohibit price gouging in the sale of drugs by requiring pharmaceutical companies to provide justification for price increases and penalize such companies if increases are deemed unreasonable (see S. 637), S1594 [28FE] (see H.R. 4158), H7488 [2AU]

——— provide better protections and support for children raised by grandparents or other kinship families outside the foster care system due to parental drug or alcohol abuse (see S. 1181), S2434 [11AP]

——— require drug manufacturers to include printed inserts containing drug information when they ship their products to pharmacies (see H.R. 5198), H9120 [20NO]

——— require drug manufacturers to publicly justify unnecessary price increases (see S. 474), S1326 [13FE]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (see S. 1391), S2770 [9MY] (see H.R. 2069), H3068 [3AP] (see H.R. 2296), H3263 [12AP]

——— require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers (see H.R. 2064), H3067 [3AP]

——— require manufacturers to justify drug price spikes and high launch prices and report on drug, device, biological, and medical supply product samples provided to health care providers (see H.R. 2113), H3127 [8AP]

——— require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements (see H.R. 4640), H8110 [11OC]

——— require pharmacies and insurance companies to improve transparency of prescription drug costs and prohibit drug manufacturers from charging U.S. consumers more for drugs than certain foreign customers (see S. 977), S2118 [1AP]

——— require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug (see H.R. 5442), H10306 [16DE]

——— support endemic fungal disease research, incentivize fungal vaccine development, and discover new antifungal therapies and diagnostics to fight infections such as valley fever (see S. 1567), S3004 [21MY] (see H.R. 2858), H4063 [21MY]

——— test the feasibility and outcomes of integrating a substance use disorder and behavioral health treatment locator tool into prescription drug monitoring programs of eligible States (see H.R. 3927), H7376 [24JY]

Dept. of Homeland Security: ensure U.S. Customs and Border Protection officers, agents, and other personnel have adequate synthetic opioid detection equipment and a process to update synthetic opioid detection capability (see H.R. 4761), H8258 [18OC]

——— establish fund for legal services for low-income landowners whose property the Federal government wants to take for border barrier construction (see H.R. 1233), H2029 [14FE]

——— establish joint task force to integrate border security operations to detect, interdict, disrupt, and prevent narcotics, such as fentanyl and other synthetic opioids, from entering U.S. (see H.R. 3722), H5726 [11JY]

——— increase number of U.S. Customs and Border Protection officers and staff and require reports that identify staffing, infrastructure, and equipment needed to enhance security at ports of entry (see S. 1004), S2239 [3AP]

——— issue strategy to improve hiring and retention of U.S. Customs and Border Protection personnel in rural or remote areas (see H.R. 1598), H2582 [7MR]

——— making supplemental appropriations for border security (see S. 811), S1898 [14MR]

——— prohibit seizing private land for a border wall (see H.R. 1234), H2029 [14FE]

——— protect U.S. Customs and Border Protection officers, agents, other personnel, and canines against potential synthetic opioid exposure (see H.R. 4739), H8257 [18OC]

——— provide provisional protected presence status for eligible Deferred Action for Childhood Arrivals program participants and provide mandatory appropriations relative to border security (see S. 166), S274 [16JA]

——— require border community stakeholder consultation before construction, installation, deployment, or operation of additional physical barriers, infrastructure, or technology between ports of entry (see H.R. 1292), H2032 [14FE]

——— rescind authority to waive Federal law to facilitate construction of border barriers (see S. 254), S742 [29JA] (see H.R. 1232), H2029 [14FE]

——— strike marijuana use, possession, and distribution as grounds of inadmissibility and removal from the country (see S. 2021), S4628 [27JN] (see H.R. 4390), H7773 [18SE]

——— support employees who carry out essential mission of the U.S. Border Patrol, Office of Field Operations, and Air and Marine Operations within U.S. Customs and Border Protection (see H. Res. 170), H2322 [4MR]

Dept. of HUD: establish a grant program to provide temporary housing to homeless individuals near high-density homeless areas that provides health and social services and targeted outreach (see H.R. 4936), H8717 [31OC]

——— provide that an individual who uses marijuana in compliance with State law may not be denied occupancy of federally assisted housing (see H.R. 2338), H3274 [18AP]

Dept. of Justice: make grants to State and local governments for programs to provide medication-assisted treatment to individuals incarcerated in the jurisdiction who are addicted to opioids (see S. 1983), S4566 [26JN] (see H.R. 3496), H5199 [26JN]

——— make procurement quotas for opioid analgesics publicly available to disclose applications requesting active ingredients and amount of opioids alloted to be produced by manufacturers (see S. 1366), S2742 [8MY] (see H.R. 2582), H3500 [8MY]

——— prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (see H.R. 493), H517 [11JA]

——— protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse position in Texas v. U.S. (see S. Res. 134), S2189 [2AP]

——— provide grants for drug disposal sites (see H.R. 3171), H4387 [10JN]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (see S. 954), S2088 [28MR] (see H.R. 2070), H3068 [3AP]

——— reauthorize Comprehensive Opioid Abuse Grant Program (see H.R. 1528), H2367 [5MR]

——— reform sentencing, prison conditions, law enforcement training, and reentry of prisoner efforts (see S. 697), S1733 [7MR] (see H.R. 1893), H2827 [26MR]

——— require registration of tableting or encapsulating machines to assist law enforcement in identifying counterfeit pill makers (see S. 989), S2189 [2AP] (see H.R. 2020), H2985 [2AP]

——— use lawfully forfeited drug seizures to increase border security (see H.R. 416), H358 [9JA]

Dept. of State: develop and maintain an international diplomatic and assistance strategy to stop the flow of illicit opioids, including fentanyl, into the U.S. (see H.R. 2780), H3923 [16MY]

——— submit report on designation of Reynosa/Los Metros faction of the Gulf Cartel, Jalisco New Generation Cartel, and Cartel Del Noreste faction of Los Zetas as foreign terrorist organizations (see H.R. 1700), H2680 [12MR]

Dept. of the Interior: establish Maya Security and Conservation Partnership Program (see S. 3131), S7208 [19DE]

Dept. of the Treasury: prepare a threat and operational analysis of drug kingpin and crime syndicate financing of terrorism, drug and human trafficking, money laundering, and other forms of illicit financing (see S. 2144), S4907 [17JY]

——— prohibit discrimination in life insurance policies based on possession of naloxone by first responsers or medical professionals (see H.R. 1832), H2755 [18MR]

Dept. of Transportation: establish a pilot program on drugged driving prevention (see H.R. 3159), H4349 [6JN]

Dept. of Veterans Affairs: allow veterans to use, possess, or transport medical marijuana and to discuss the use of medical marijuana with departmental physicians as authorized by State or tribal law (see S. 445), S1275 [12FE] (see H.R. 1151), H1525 [12FE]

——— authorize health care providers to provide recommendations and opinions to veterans regarding participation in State marijuana programs (see H.R. 1647), H2614 [8MR]

——— carry out a clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (see S. 179), S293 [17JA] (see H.R. 712), H1170 [23JA]

——— conduct and support research on the efficacy and safety of medicinal marijuana (see H.R. 747), H1209 [24JA]

——— conduct review of deaths of certain veterans who committed suicide (see H.R. 100), H204 [3JA]

——— eliminate copayments for medicines relative to preventive health services (see S. 1573), S3004 [21MY] (see H.R. 3932), H7376 [24JY]

——— eliminate sunset date and expand eligibility for Veterans Choice Program, provide access to walk-in clinics, expand pharmacy operating hours, encourage peer reviews, and expand telemedicine (see H.R. 23), H201 [3JA]

——— ensure certain departmental medical facilities have physical locations for disposal of controlled substances or medications (see H.R. 4817), H8456 [23OC]

——— enter into an agreement with a federally funded research and development center to conduct surveys to measure cannabis use by veterans (see H.R. 2676), H3727 [10MY]

——— furnish Vet Center counseling and mental health services to National Guard, Reserve, or Coast Guard members who participated in drug interdiction or emergency or disaster response (see H.R. 1812), H2754 [18MR]

——— improve mental health care (see S. 785), S1845 [13MR]

——— prohibit denial of benefits due to participation in a State-approved marijuana program (see H.R. 2191), H3217 [9AP]

——— prohibit from denying home loans for veterans who legally work in the marijuana industry on the basis of the nature of such work (see S. 3087), S7156 [18DE] (see H.R. 5477), H12209 [18DE]

——— provide for a policy on medicinal cannabis (see H.R. 2675), H3726 [10MY]

——— provide training in use of medical cannabis for all departmental primary care providers (see H.R. 2677), H3727 [10MY]

Diseases and disorders: facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts (see S. 2481), S5539 [17SE] (see H.R. 3460), H5165 [25JN]

——— facilitate effective research on, and treatment of, neglected tropical diseases, including Ebola, through coordinated domestic and international efforts (see H.R. 826), H1242 [28JA]

Drug abuse: combat heroin epidemic and assist forensic labs with addressing seized drug identification backlogs (see H.R. 817), H1242 [28JA]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (see S. 1365), S2742 [8MY] (see H.R. 2569), H3499 [8MY]

——— recognize addiction as a disease and support efforts to prevent, treat, and destigmatize substance use disorder and addiction (see H. Res. 714), H9057 [19NO]

FDA: address abuse of citizen petition process by brand drug manufacturers (see S. 660), S1659 [5MR]

——— allow for importation of affordable and safe insulin by wholesale distributors, pharmacies, and individuals (see H.R. 1478), H2314 [28FE]

——— allow rejection of a citizen petition if it is believed the primary purpose of the petition is to delay approval of a pending drug application and refer such petitioners to the FTC (see S. 1169), S2433 [11AP] (see H.R. 2455), H3404 [1MY]

——— amend exclusivity period granted to a first generic drug application (see S. 3092), S7156 [18DE]

——— amend mission statement to require the agency to address the nation’s prescription opioid addiction epidemic (see S. 417), S1133 [7FE]

——— clarify process for denying certain petitions whose primary purpose is to delay approval of an application submitted relative to certain drugs (see H.R. 2387), H3303 [29AP]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (see S. 2740), S6299 [30OC] (see H.R. 269), H280 [8JA] (see H.R. 3443), H5075 [24JN]

——— clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (see S. 1617), S3059 [22MY] (see H.R. 1503), H2366 [5MR]

——— codify policy of requiring drug products to contain an active moiety that has not been used in a previously approved product in granting new chemical entity exclusivity (see S. 1636), S3104 [23MY]

——— ensure eligible product developers have competitive access to approved drugs and licensed biological products to enable development and testing of new products (see H.R. 985), H1362 [5FE]

——— ensure valid generic drugs may enter the market by removing generic drug exclusivity period from any generic company that enters into pay-for-delay settlements with brand-name drug manufacturers (see H.R. 1506), H2366 [5MR]

——— establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs (see S. 3133), S7208 [19DE] (see H.R. 5497), H12289 [19DE]

——— establish procedures relative to approval of opioid drugs (see S. 418), S1133 [7FE]

——— expand tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever (see H.R. 4553), H8080 [27SE]

——— hold pharmaceutical companies accountable for dubious marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (see S. 1584), S3005 [21MY] (see H.R. 2917), H4118 [22MY]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and preventing providers from dispensing drugs remotely, by mail, or telemedicine (see S. 3072), S7113 [17DE] (see H.R. 4399), H7834 [19SE]

——— increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (see S. 1209), S2435 [11AP] (see H.R. 3812), H5999 [17JY]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application (see H.R. 938), H1341 [31JA]

——— invest in qualified clinical testing for high-risk, high-reward drugs that address unmet medical needs to treat rare and life-threatening diseases (see H.R. 5402), H10123 [11DE]

——— limit exclusive approval or licensure of orphan drugs (see H.R. 4712), H8226 [17OC]

——— make permanent the policy to speed up time for biosimilar products to get approved and made available to consumers (see S. 1140), S2432 [11AP] (see H.R. 2011), H2938 [1AP]

——— permanently reauthorize Rare Pediatric Disease Designation Program to issue priority review vouchers to encourage treatments for rare pediatric diseases (see H.R. 4439), H7865 [20SE]

——— prevent abuse of dextromethorphan by restricting over-the-counter sales of cough medicines to teenagers and prohibiting bulk distribution of unfinished dextromethorphan to unauthorized persons (see H.R. 863), H1332 [30JA]

——— prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 344), S919 [6FE] (see H.R. 990), H1389 [6FE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (see S. 340), S867 [5FE] (see H.R. 965), H1361 [5FE]

——— prohibit opioids from being labeled for intended use to treat long-term chronic pain, except for cancer pain, end-of-life care, or when other pain management treatments are inadequate (see S. 2089), S4806 [11JY]

——— prohibit sale of poppy seeds, or food that contains poppy seeds, with unsafe levels of certain opiates (see S. 1016), S2240 [3AP] (see H.R. 2078), H3068 [3AP]

——— provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application (see H.R. 4244), H7558 [9SE]

——— provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries (see S. 658), S1659 [5MR]

——— provide for publication of a list of licensed biological products (see H.R. 1520), H2366 [5MR]

——— provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad (see S. 2161), S4947 [18JY]

——— reauthorize innovation projects (see H.R. 4633), H8110 [11OC]

——— require label of drugs with an increased risk of suicide or depression to prominently detail those side effects (see H.R. 4404), H7834 [19SE]

——— require labeling of country of origin of a drugs active ingredients (see H.R. 5381), H10015 [10DE]

——— require labels of drugs that contain an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient (see S. 3021), S6992 [11DE] (see H.R. 2074), H3068 [3AP]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (see S. 659), S1659 [5MR] (see H.R. 4850), H8457 [23OC]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 1449), S2815 [14MY] (see H.R. 2732), H3789 [14MY]

——— restrict direct-to-consumer drug advertising (see H.R. 4106), H7480 [30JY]

——— revoke approval of one opioid pain medication for each new opioid pain medication approved (see S. 419), S1133 [7FE]

——— shorten exclusivity period for brand name biological products (see H.R. 3379), H5005 [20JN]

——— shorten monopoly periods for prescription drugs that are subjects of sudden price hikes (see S. 366), S919 [6FE]

——— speed up approvals of lower-cost, generic, and ‘‘follow-on’’ insulin products (see S. 2103), S4807 [11JY] (see H.R. 5444), H10608 [17DE]

——— strengthen regulation of compounding drugs by pharmacies (see H.R. 1959), H2915 [28MR]

——— update labeling of certain drugs with outdated labeling (see S. 1897), S3843 [19JN]

FEC: prohibit a separate segregated fund of a corporation which manufactures opioids from making contributions or expenditures in connection with Federal elections (see H.R. 5196), H9120 [20NO]

Federal aid programs: recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 59), H719 [17JA]

Federal employees: remove limitations on Federal employment for individuals legally using marijuana according to laws of the State in which they reside (see H.R. 1687), H2679 [12MR]

Federal-State relations: provide that Federal law shall not preempt State law in enforcement of Controlled Substances Act criminal penalties for marijuana (see H.R. 2012), H2938 [1AP]

Financial institutions: create protections for depository institutions that provide financial services to legitimate marijuana-related businesses (see S. 1200), S2434 [11AP] (see H.R. 1595), H2582 [7MR]

Firearms: amend laws relative to sale, purchase, shipment, receipt, or possession of a firearm or ammunition by a user of medical marijuana (see H.R. 2071), H3068 [3AP]

Foreign aid: withhold assistance from countries that do not monitor or prosecute production or distribution of illicit fentanyl and other synthetic drugs or do not require registration of tableting and encapsulating machines (see S. 400), S1132 [7FE] (see H.R. 1098), H1461 [7FE]

Foreign countries: impose sanctions relative to foreign traffickers of illicit opioids (see S. 1044), S2270 [4AP] (see H.R. 2226), H3253 [10AP] (see H.R. 2483), H3439 [2MY]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (see S. 1224), S2485 [29AP] (see H.R. 2374), H3302 [29AP]

——— issue rules to promote competition and help consumers save money by giving them freedom to choose where they buy prescription pet medications (see S. 1290), S2613 [2MY] (see H.R. 1607), H2582 [7MR]

——— prohibit anticompetitive use of patents by drug product manufacturers (see S. 1416), S2770 [9MY] (see H.R. 4398), H7834 [19SE] (see H.R. 5133), H8958 [18NO]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (see S. 1227), S2485 [29AP] (see H.R. 2376), H3302 [29AP]

GAO: conduct study on how virtual currencies and online marketplaces are used to facilitate sex and drug trafficking (see S. 410), S1133 [7FE] (see H.R. 502), H517 [11JA]

——— evaluate and report on the in-patient and outpatient drug treatment capacity, availability, and needs of the U.S. (see H.R. 1303), H2038 [15FE]

——— study role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations (see S. 1532), S2924 [16MY] (see H.R. 3223), H4626 [12JN]

——— study ways to increase reporting of missing Indians and effects of substance abuse on violent crime in tribal communities (see S. 1893), S3843 [19JN]

Health: address high costs of health care, prescription drugs, and health insurance coverage (see H.R. 1332), H2100 [25FE]

——— anniversary of eradication of smallpox and recognition of importance of vaccinations and immunizations (see H. Res. 592), H7989 [25SE]

——— create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices (see H.R. 5382), H10015 [10DE]

——— exempt sunscreen from over-the-counter medication bans in schools, encourage community and youth-related entities to provide access to sunscreen and sun-protective clothing, and teach sun-safe behaviors (see H. Res. 323), H3270 [15AP]

——— extend certain public health programs (see H.R. 4378), H7772 [18SE]

——— extend certain public health programs (H.R. 4378), consideration (see H. Res. 564), H7834 [19SE]

——— lower health care costs by ending surprise medical bills, reducing drug prices, and improving health care transparency, public health, and exchange of health information (see S. 1895), S3843 [19JN]

——— promote transparency in health care pricing (see H.R. 1409), H2271 [27FE]

——— protect health care of all Americans, especially those with preexisting conditions, and ensure a replacement for the Patient Protection and Affordable Care Act if it is struck down in Texas v. U.S. (see H. Res. 280), H2986 [2AP]

——— recognize importance of vaccinations and immunizations (see S. Res. 165), S2435 [11AP] (see H. Res. 179), H2368 [5MR]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (see H. Res. 377), H3787 [14MY]

——— require certain drug manufacturers entering into settlement agreements for violations of law to make supplemental payments to be used to increase medical research funding (see H.R. 5031), H8739 [8NO]

——— support the right to affordable, quality health care (see S. Res. 273), S4729 [9JY]

Health care professionals: acknowledge contributions of addiction professionals and their commitment to treating individuals with substance use disorders through recognized standards of education, training, and competencies (see H. Res. 419), H4216 [3JN]

——— improve and expand training for future and current physicians and mid-level health care providers on treating pain and prescribing opioids (see H. Con. Res. 8), H1283 [29JA]

——— require certain practitioners authorized to prescribe controlled substances to complete continuing education (see S. 1448), S2815 [14MY] (see H.R. 2734), H3789 [14MY]

——— require prescribers of controlled substances to complete training on treating patients with opioid and other substance use disorders and incorporate such training in medical school curricula (see H.R. 4974), H8724 [1NO]

Immigration: clarify admissibility and deportability of aliens acting in accordance with State and foreign marijuana laws (see H.R. 2703), H3788 [14MY]

——— provide appropriations to secure the border between the U.S. and Mexico (see H.R. 796), H1217 [25JA]

——— provide exception from grounds for inadmissibility for participation in a cannabis business operating in compliance with State law (see S. 3097), S7156 [18DE]

——— require new legal permanent residents to pay a fee, deposit such fees in newly established Border Security Enhancement Fund, and authorize use of such Fund for border security and immigration improvements (see S. 643), S1621 [4MR]

Immigration and Nationality Act: deem certain cartel organizations to be foreign terrorist organizations (see H.R. 5509), H12289 [19DE]

Insulin: prohibit pharmacy benefit managers and insurers from receiving rebates for insulin products for which the manufacturer has complied with list price reduction requirements and require certain deductible waivers (see S. 2199), S4966 [22JY] (see H.R. 4906), H8594 [29OC]

Insurance: bring stability to the individual insurance market, make insurance coverage more affordable, lower prescription drug prices, and improve Medicaid (see S. 3), S19 [3JA]

——— create safe harbor for insurers that provide services to legitimate marijuana-related businesses (see H.R. 4074), H7467 [25JY]

——— ensure common medications, devices, and screenings used to treat chronic conditions are covered without out-of-pocket costs (see H.R. 4457), H7900 [24SE]

——— establish a public health plan (see S. 981), S2188 [2AP] (see H.R. 2000), H2937 [1AP]

——— require a group health plan to provide an exceptions process for any medication step therapy protocol (see S. 2546), S5706 [25SE] (see H.R. 2279), H3255 [10AP]

——— require group health plans and group or individual health insurance coverage to provide coverage for over-the-counter contraceptives (see S. 1847), S3476 [13JN] (see H.R. 3296), H4700 [14JN]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (see S. 741), S1792 [12MR] (see H.R. 1730), H2716 [13MR]

——— require health plan oversight of pharmacy benefit manager services (see H.R. 5304), H9256 [4DE]

Law enforcement: develop a national strategy to combat financial networks of transnational organized criminals (see H.R. 1387), H2270 [27FE]

——— establish nonpartisan commission on immigration reform and border security (see H.R. 1283), H2032 [14FE]

——— focus limited Federal resources on the most serious offenders by modifying sentencing guidelines for certain drug offenses (see S. 2850), S6567 [13NO]

——— provide for enhanced penalties for certain offenses relative to controlled substances containing fentanyl (see H.R. 1655), H2614 [8MR]

——— stop production of fentanyl and its trafficking into the U.S. from China (see H.R. 1542), H2367 [5MR]

——— use forfeited criminal proceeds from Treasury Forfeiture Fund for border security measures, including a border wall (see S. 293), S799 [31JA]

——— use forfeited criminal proceeds resulting from prosecution of Joaquín A. Guzmán Loera (El Chapo) or other felony drug convictions for border security measures, including a border wall (see S. 25), S19 [3JA] (see H.R. 714), H1170 [23JA]

Marijuana: allow State and tribal regulation, maintain application of certain criminal offenses relative to marijuana, prohibit its sale to individuals under 21, and study effects of legalization (see S. 1028), S2269 [4AP] (see H.R. 2093), H3099 [4AP] (see H.R. 3754), H5824 [15JY]

——— create a safe harbor for insurers engaging in the business of insurance in connection with a cannabis-related business (see S. 2201), S4966 [22JY]

——— decriminalize, expunge prior convictions, tax products to create programs for those adversely affected by War on Drugs, and provide assistance and collect data on small businesses (see S. 2227), S5012 [23JY] (see H.R. 3884), H7240 [23JY]

——— decriminalize, use tax revenues to assist certain small businesses, research effects on driving and health, restrict advertising to protect children, and expunge certain marijuana-related convictions (see S. 1552), S2962 [20MY] (see H.R. 2843), H4009 [20MY]

——— decriminalize marijuana at the Federal level and leave States the power to regulate marijuana similar to the power to regulate alcohol (see H.R. 420), H358 [9JA]

——— develop national cannabis research agenda, collect data on cannabis use and impacts on health outcomes, change controlled substance classification of cannabis, and streamline DEA approval of research (see S. 2400), S5248 [31JY] (see H.R. 4322), H7705 [12SE]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans (see H.R. 127), H205 [3JA]

——— improve medical research by simplifying registration process to conduct research, facilitating access for such research, and allowing private manufacture and distribution for research purposes (see H.R. 3797), H5998 [17JY]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 601), H674 [16JA]

——— limit application of Federal laws to distribution and consumption (see H.R. 1588), H2581 [7MR]

——— make marijuana legal at the Federal level, incentivize States to change marijuana laws that disproportionately impact minority communities, and allow retroactive review of marijuana sentences (see S. 597), S1593 [28FE]

——— prohibit Federal interference with State marijuana policies (see S. 2030), S4628 [27JN] (see H.R. 3546), H5256 [27JN]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (see H.R. 1456), H2313 [28FE]

——— provide for legitimate use of medicinal marijuana in accordance with State laws (see H.R. 171), H207 [3JA]

——— provide for taxation and regulation of marijuana products (see S. 420), S1133 [7FE] (see H.R. 1120), H1491 [8FE]

——— reduce gap between Federal and State marijuana policy (see S. 421), S1133 [7FE] (see H.R. 1119), H1491 [8FE]

——— reschedule marijuana under the Controlled Substances Act (see H.R. 4323), H7705 [12SE]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (see S. 2032), S4628 [27JN]

——— urge action to increase equity within the legal cannabis marketplace (see H. Res. 163), H2315 [28FE]

Medicaid: allow for payments to States for substance abuse services furnished to inmates in public institutions (see H.R. 2511), H3440 [2MY]

——— exclude authorized generic drugs from calculation of average manufacturer price for purposes of drug rebate program (see S. 1785), S3319 [11JN] (see H.R. 3276), H4694 [13JN]

——— expand permitted uses of drug price information disclosed to States under drug rebate program to make prescription drugs more affordable (see S. 2252), S5062 [24JY]

——— extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (see H.R. 1839), H2760 [21MR]

——— improve transparency and prevent use of abusive spread pricing and related practices (see H.R. 5281), H9221 [3DE]

——— prevent misclassification of drugs for purposes of the drug rebate program (see S. 205), S586 [24JA] (see H.R. 937), H1341 [31JA]

——— prohibit States receiving Federal medical assistance for medication-assisted treatment for substance use disorders from imposing utilization control policies or procedures (see H.R. 3925), H7241 [23JY]

——— provide coverage for services for treatment of psychiatric or substance use disorders furnished to certain individuals in an institution for mental diseases (see H.R. 5006), H8738 [8NO]

——— remove matching requirement for a territory to use specially allocated Federal funds for Medicare covered part D drugs for low-income individuals (see H.R. 2172), H3216 [9AP] (see H.R. 4699), H8198 [16OC]

——— sunset the limit on maximum rebate amount for single source drugs and innovator multiple source drugs (see H.R. 107), H205 [3JA]

Medicare: adjust part D prescription drug cost-sharing reductions for low-income individuals (see H.R. 2757), H3841 [15MY]

——— allow prescription drug plan sponsors and Medicare Advantage organizations to share with enrollees a portion of savings from switching to lower cost therapeutic alternative medications (see S. 3000), S6904 [9DE]

——— allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see S. 62), S103 [9JA]

——— clarify treatment of pass-through status under outpatient payment system for certain drugs (see H.R. 5057), H8783 [12NO]

——— combat opioid crisis by promoting access to non-opioid treatments in the hospital outpatient setting (see S. 3067), S7113 [17DE] (see H.R. 5172), H9056 [19NO]

——— coordinate programs to prevent and treat obesity (see S. 595), S1593 [28FE] (see H.R. 1530), H2367 [5MR]

——— deliver a meaningful drug benefit and lower prescription drug prices (see S. 2650), S5922 [21OC] (see H.R. 4769), H8297 [21OC]

——— eliminate cost-sharing for biosimilar biological products furnished under part B (see H.R. 4597), H8089 [1OC]

——— eliminate resource requirement for low-income subsidy eligibility under part D (see H.R. 4628), H8101 [8OC]

——— enhance prescription drug affordability by expanding access to assistance with out-of-pocket costs under part D for low-income seniors and individuals with disabilities (see S. 691), S1733 [7MR] (see H.R. 4583), H8088 [1OC]

——— ensure equal access of beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage (see H.R. 4946), H8717 [31OC]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see H.R. 3772), H5910 [16JY]

——— establish an improved Medicare for All national health insurance program (see S. 1129), S2386 [10AP] (see H.R. 1384), H2269 [27FE]

——— establish Medicare for America program to provide comprehensive health insurance coverage for all U.S. citizens (see H.R. 2452), H3404 [1MY]

——— establish part E public health plans available to everyone (see S. 1261), S2569 [1MY] (see H.R. 2463), H3404 [1MY]

——— expand eligibility for low-income subsidies under part D (see H.R. 4620), H8101 [8OC]

——— extend coverage of immunosuppressive drugs for kidney transplant patients (see H.R. 5534), H12297 [23DE]

——— improve efficiency of appeals process (see S. 3078), S7113 [17DE]

——— make premium and cost-sharing subsidies available to low-income part D beneficiaries residing in Puerto Rico or other U.S. territories (see S. 3029), S7026 [12DE] (see H.R. 4195), H7511 [20AU]

——— negotiate prices of excessively costly life-sustaining prescription drugs (see H.R. 5039), H8783 [12NO]

——— permanently authorize Limited Income Newly Eligible Transition (LI NET) Program to provide transitional coverage and retroactive part D prescription drug coverage for certain low-income individuals (see S. 1999), S4627 [27JN] (see H.R. 3029), H4174 [28MY]

——— prevent catastrophic out-of-pocket spending on prescription drugs for seniors and individuals with disabilities (see S. 475), S1326 [13FE]

——— prohibit prescription drug plan sponsors and Medicare Advantage prescription drug organizations from retroactively reducing payment on clean claims submitted by pharmacies (see S. 988), S2189 [2AP] (see H.R. 789), H1211 [24JA] (see H.R. 803), H1217 [25JA]

——— promote access to opioid treatments and require coverage of medication assisted treatment, overdose reversal medications, and recovery support services by health plans without cost-sharing requirements (see S. 1424), S2786 [13MY]

——— provide a monthly out-of-pocket cost-sharing maximum for enrollees who incur a significant portion of costs for covered part D drugs towards the annual out-of-pocket threshold during a month (see S. 2911), S6718 [20NO]

——— provide certain low-income territorial residents with automatic eligibility for premium and cost-sharing subsidies (see H.R. 4666), H8111 [11OC]

——— provide coverage for generic and biosimilar medications on part D plan formularies and ensure generic drugs are placed on formulary tiers so beneficiaries are not charged brand name drug prices (see H.R. 4913), H8677 [30OC]

——— provide coverage of addiction counselor services under part B (see S. 2412), S5311 [1AU]

——— provide for a cap on beneficiary liability under part D (see H.R. 4649), H8111 [11OC]

——— provide for a temporary payment increase for certain biosimilar biological products to encourage development and use of such products (see H.R. 4455), H7865 [20SE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (see H.R. 4661), H8111 [11OC]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (see H.R. 4655), H8111 [11OC]

——— provide for distribution of additional residency positions to help combat the opioid crisis (see S. 2892), S6669 [19NO] (see H.R. 2439), H3403 [1MY] (see H.R. 3414), H5036 [21JN]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans (see H.R. 4669), H8111 [11OC]

——— provide for negotiation of lower covered part D drug prices on behalf of beneficiaries and establishment and application of a formulary by the Dept. of HHS under part D (see S. 99), S142 [10JA] (see H.R. 448), H462 [10JA]

——— provide for pharmacy benefits manager standards under the prescription drug program and Medicare Advantage program to further transparency of payment methodology of pharmacies (see H.R. 1035), H1458 [7FE]

——— provide greater transparency of discounts provided by drug manufacturers by establishing requirements for pharmacy-negotiated price concessions (see S. 2247), S5062 [24JY]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to disclose aggregate rebates and what proportion of those rebates go to beneficiaries (see S. 476), S1326 [13FE] (see H.R. 2115), H3127 [8AP]

——— provide information on vaccines for seniors as part of the Medicare & You handbook and ensure treatment of cost-sharing for vaccines under part D is consistent with treatment under part B (see S. 1872), S3477 [13JN] (see H.R. 5076), H8826 [13NO]

——— provide low-income subsidy enrollees in part D with information about less expensive prescription drug plan options (see H.R. 4632), H8110 [11OC]

——— require certain manufacturers to report drug pricing information (see S. 2051), S4677 [28JN] (see H.R. 2087), H3099 [4AP]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation (see H.R. 4619), H8101 [8OC] (see H.R. 4663), H8111 [11OC]

——— require drug manufacturers to provide rebates for drugs furnished under part B for which the growth in average sales price has exceeded inflation (see S. 2081), S4773 [10JY]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (see S. 640), S1621 [4MR] (see H.R. 1034), H1458 [7FE]

——— require manufacturers of certain single-dose vial drugs payable under part-B to provide rebates relative to amounts of such drugs discarded (see S. 551), S1437 [25FE]

——— require prescription drug plan sponsors to include real-time benefit information as part of such sponsor’s electronic prescription program (see H.R. 3408, 3415), H5036 [21JN]

——— require prescription drug plans and Medicare Advantage prescription drug plans to report potential fraud, waste, and abuse to Dept. of HHS under part D (see S. 1505), S2924 [16MY]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see H.R. 275), H281 [8JA]

——— treat a pharmacy counter refusal as a coverage determination under part D (see S. 1861), S3476 [13JN] (see H.R. 3924), H7241 [23JY]

Medicare/Medicaid: eliminate cost-sharing relative to coverage of insulin as a covered part D drug under Medicare or as a covered outpatient drug under Medicaid (see H.R. 366), H356 [9JA]

——— lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers (see S. 2543), S5706 [25SE]

——— promote ability of beneficiaries to access their personal medical claim data through a mobile health record application (see H.R. 1390), H2270 [27FE]

——— provide Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information (see S. 801), S1898 [14MR] (see H.R. 1264), H2031 [14FE] (see H.R. 1781), H2744 [14MR]

——— repeal medical device tax and extend certain programs and tax incentives (see S. 3001), S6904 [9DE]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (see S. 1437), S2787 [13MY]

Members of Congress: require Members to participate in random drug testing (see H. Con. Res. 22), H2271 [27FE]

Meningitis B Awareness Day: designate (see S. Res. 159), S2435 [11AP] (see H. Res. 313), H3256 [10AP]

Mental health: strengthen parity in mental health and substance use disorder benefits (see S. 1576), S3005 [21MY] (see S. 1737), S3251 [5JN] (see H.R. 2848), H4009 [20MY] (see H.R. 2874), H4063 [21MY] (see H.R. 3165), H4387 [10JN]

Methadone: revise Dept. of HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs to include testing for methadone use and require Dept. of Transportation to include testing for methadone use in drug tests (see H.R. 2285), H3255 [10AP]

National Academies of Sciences, Engineering, and Medicine: conduct review of deaths of certain veterans who committed suicide (see S. 2991), S6888 [5DE]

National Adult Hepatitis B Vaccination Awareness Day: designate (see S. Res. 177), S2516 [30AP] (see H. Res. 331), H3339 [30AP]

National Alcohol and Drug Addiction Recovery Month: observance (see S. Res. 379), S6156 [24OC]

National Criminal Justice Commission: establish (see S. 2434), S5311 [1AU]

National Highway Traffic Safety Administration: conduct study on unsafe use of electric scooters (see H.R. 5426), H10258 [12DE]

National objectives: acknowledge that the War on Drugs has been a failed policy and apologize to individuals and communities victimized by this policy (see H. Res. 747), H9347 [6DE]

National Recovery Month: designate (see H. Res. 586), H7902 [24SE]

Native Americans: authorize a special behavioral health program for Indians (see S. 3126), S7208 [19DE]

——— protect legal production, purchase, and possession of marijuana by Indian tribes (see H.R. 1416), H2271 [27FE]

NIH: conduct or support further comprehensive research for creation of a universal influenza vaccine (see S. 570), S1493 [26FE] (see H.R. 1371), H2233 [26FE]

——— reauthorize innovation projects (see H.R. 4667), H8111 [11OC]

NSF: support research on opioid addiction (see S. 2354), S5247 [31JY] (see H.R. 3153), H4348 [6JN]

Office of National Drug Control Policy: evaluate effectiveness of federally funded programs tasked with reducing demand for illicit substances and publish information on such programs (see H.R. 3820), H7149 [18JY]

——— make technical corrections to reauthorization (see H.R. 3889), H7240 [23JY]

Office of the Director of National Intelligence: assess drug trafficking and human trafficking and smuggling in Mexico and Northern Triangle countries of El Salvador, Guatemala, and Honduras (see H.R. 3720), H5726 [11JY]

Office of the U.S. Trade Representative: establish position of Chief Pharmaceutical Negotiator responsible for trade negotiations and agreements relative to foreign governments that fail to reward U.S. pharmaceutical innovation (see H.R. 2209), H3252 [10AP]

Orphan Drug Act: affirm importance, commend life-saving accomplishments, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases (see H. Res. 242), H2755 [18MR]

Patents: clarify and improve patent infringement litigation process for biological products to expedite getting generic drugs to market (see H.R. 3991), H7463 [25JY]

——— provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (see S. 440), S1275 [12FE]

Patient Protection and Affordable Care Act: repeal amendments which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements (see S. 1089), S2328 [9AP]

Patient-Centered Outcomes Research Institute: reauthorize (see S. 2897), S6669 [19NO]

Pharmaceuticals: prohibit biological product manufacurers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market (see H.R. 1499), H2366 [5MR]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 64), S103 [9JA] (see H.R. 1344), H2100 [25FE] (see H.R. 1499), H2366 [5MR]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (see H.R. 2375), H3302 [29AP]

——— shorten monopoly periods for prescription drugs that are the subjects of sudden price hikes (see H.R. 1188), H1582 [13FE]

Philippines: condemn state-sanctioned killings as part of the ‘‘War on Drugs,’’ arrest of human rights defenders and journalists, and continued detention of Leila De Lima, and call for immediate release (see S. Res. 142), S2270 [4AP] (see H. Res. 233), H2745 [14MR]

Postal Service: enter into an agreement with U.S. Customs and Border Protection to train Postal Service employees to identify illicit packages (see S. 1373), S2743 [8MY]

——— establish comprehensive organizational strategy to combat use of the mail in distribution of illicit drugs (see S. 2974), S6858 [4DE]

Presidents of the U.S.: prohibit creation of manufactured emergencies in order to build border walls during a Government shutdown (see H.R. 522), H518 [11JA]

Public safety officers: provide opioid receptor antagonists, including naloxone, to first responders for personal use to prevent accidental overdose due to incidental contact with dangerous drugs (see H.R. 1823), H2754 [18MR]

Puerto Rico: improve collection and publication of statistics (see H.R. 1405), H2270 [27FE]

Red Ribbon Week: support goals and ideals (see S. Res. 366), S5922 [21OC]

Research: encourage development and use of new antimicrobial drugs in order to treat antibiotic-resistant infections (see S. 1712), S3215 [4JN] (see H.R. 4100), H7479 [30JY]

Safety: facilitate responsible, informed dispensing of controlled substances and other prescribed medications (see H.R. 4810), H8455 [23OC]

SBA: decriminalize cannabis and establish an Equitable Licensing Grant Program (see H.R. 3544), H5256 [27JN]

——— ensure that certain entrepreneurial development services are made available to cannabis-related legitimate businesses and service providers (see H.R. 3543), H5256 [27JN]

——— ensure that certain loan programs are made available to cannabis-related legitimate businesses and service providers (see H.R. 3540), H5256 [27JN]

Shipping industry: require screening of all international mail and express cargo inbound into the U.S. from high-risk countries to detect and prevent importation of illicit fentanyl and other illicit synthetic opioids (see S. 2323), S5195 [30JY] (see H.R. 4102), H7479 [30JY]

Social Security: reform (see H.R. 5392), H10123 [11DE]

——— remove barriers to access to residential substance use disorder treatment services under Medicaid and State Children’s Health Insurance Program (see H.R. 5232), H9168 [21NO]

Sports: establish criminal penalties and civil remedies for doping fraud violations at major international competitions and require sharing of information with U.S. Anti-Doping Agency (see S. 259), S742 [29JA] (see H.R. 835), H1282 [29JA]

——— improve integrity and safety of horseracing by requiring a uniform anti-doping and medication control program enforced by an independent anti-doping organization (see S. 1488), S2884 [15MY]

——— improve integrity and safety of horseracing by requiring a uniform anti-doping and medication control program enforced by an independent Horseracing Anti-Doping and Medication Control Authority (see S. 1820), S3363 [12JN] (see H.R. 1754), H2742 [14MR]

States: protect States and individuals in States that have laws which permit the use of marijuana (see H.R. 1455), H2313 [28FE]

——— require use of prescription drug monitoring programs and facilitate information sharing among States that receive Federal funding to combat opioid abuse (see S. 516), S1383 [14FE] (see H.R. 3974), H7463 [25JY]

Substance Abuse and Mental Health Services Administration: award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction (see H.R. 1302), H2038 [15FE]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: provide funding for programs and activities (see S. 2102), S4807 [11JY] (see H.R. 4460), H7901 [24SE]

Taxation: allow deductions and credits relative to expenditures in connection with marijuana sales conducted in compliance with State law (see S. 422), S1133 [7FE] (see H.R. 1118), H1491 [8FE]

——— authorize designation of additional taxable vaccines (see S. 1654), S3105 [23MY] (see H.R. 1973), H2916 [28MR]

——— establish an excise tax on certain prescription drugs which have been subject to a price spike (see S. 378), S1131 [7FE] (see H.R. 1093), H1461 [7FE]

——— establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (see S. 425), S1133 [7FE] (see H.R. 4631), H8110 [11OC] (see H.R. 4793), H8387 [22OC]

——— include certain over-the-counter medical and menstrual care products as qualified medical expenses in order to allow use of health savings accounts and flexible spending accounts for such products (see H.R. 1922), H2884 [27MR]

——— prohibit deduction for prescription drug advertising and promotional expenses (see S. 73), S141 [10JA] (see H.R. 4711), H8226 [17OC]

——— provide a tax credit for homebuyers purchasing residences in residential recovery zones (see H.R. 3790), H5998 [17JY]

——— strike provision of American Opportunity Tax Credit that denies credit to students with felony drug convictions (see S. 2553), S5747 [26SE] (see H.R. 4518), H8053 [26SE]

Television: urge VH1 (televison network) to cancel ‘‘Cartel Crew’’ and reconsider its standards in developing shows (see S. Res. 444), S6756 [21NO]

Transportation: improve drug testing for transportation-related activities (see S. 2979), S6858 [4DE]

Trump, President: terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (see S.J. Res. 10), S1594 [28FE] (see S.J. Res. 54), S5407 [10SE] (see H.J. Res. 46), H2046 [22FE] (see H.J. Res. 75), H7835 [19SE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), consideration (see H. Res. 144), H2099 [25FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), consideration (see H. Res. 591), H7988 [25SE]

U.S. Anti-Doping Agency: reauthorize (see H.R. 5373), H9387 [9DE]

Unemployment: require substance abuse risk assessment and targeted drug testing as a condition for receipt of unemployment compensation (see H.R. 1121), H1491 [8FE]

Venezuela: provide humanitarian relief, advance a constitutional and democratic solution to political crisis, address economic reconstruction, and combat public corruption, narcotics trafficking, and money laundering (see S. 1025), S2240 [3AP]

Veterans: expand and study efficacy of veterans treatment court programs in order to assist justice-involved veterans (see H. Res. 698), H8878 [14NO]

World Hepatitis Day: observance (see H. Res. 505), H7151 [18JY]

World Tuberculosis Day: support goals (see S. Res. 119), S1900 [14MR]

Declarations

President Trump’s declaration of a national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border does not qualify under National Emergencies Act: several former national security officials, S5653–S5655 [24SE]

Essays

State of the Union: Livia Greenberg, S795 [31JA]

——— Megan Benway, S766 [30JA]

Factsheets

12 Key Federal Policies That Have Contributed to the U.S. Racial Wealth and Income Gap: Network Lobby for Catholic Social Justice (organization), H7555 [9SE]

Letters

Anti-Doping Act: Representative Nadler, Committee on the Judiciary (House), H8343 [22OC]

——— Representative Pallone, Committee on Energy and Commerce (House), H8343 [22OC]

Border security funding and immigration reform: President Trump, H294 [9JA]

——— Russell T. Vought, OMB, S43 [8JA], S1570 [28FE], H588 [15JA]

Dept. of HHS demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments: Vidor E. Friedman, American College of Emergency Physicians, H4639 [13JN]

Dept. of HHS negotiation of lower covered Medicare part D prescription drug prices for beneficiaries: Keith Hall, CBO, S3023 [22MY]

——— Senator Grassley, Committee on Finance (Senate), S3023 [22MY]

DHS Opioid Detection Resilience Act: Representative Bennie G. Thompson, Committee on Homeland Security (House), H9368 [9DE]

——— Representative Neal, Committee on Ways and Means (House), H9368 [9DE]

Lower Drug Costs Now Act: Sara Stewart, H10109 [11DE]

——— several biotechnology organizations, H10097 [11DE]

——— several pharmaceutical companies, H10130 [12DE]

ONDCP Technical Corrections Act: Representative Cummings, Committee on Oversight and Reform (House), H8167 [16OC]

——— Representative Pallone, Committee on Energy and Commerce (House), H8167 [16OC]

Over-the-Counter Drug Safety, Innovation, and Reform Act: Senator Braun, S1893 [14MR]

Payment Commission Data Act: Francis J. Crosson, Medicare Payment Advisory Commission, H8526 [28OC]

Secure and Fair Enforcement (SAFE) Banking Act: Aaron Smith, National Cannabis Industry Association, E1440 [14NO]

——— Ademola Oyefeso, United Food and Commercial Workers International Union, E1216 [26SE]

——— Alessandro DiNello, Mid-Size Bank Coalition of America, E1217 [26SE]

——— Basil Thomson, National Armored Car Association, E1442 [14NO]

——— Becky Dansky, Safe and Responsible Banking Alliance, E1230 [27SE]

——— Betsy Laird, International Council of Shopping Centers, E1240 [1OC]

——— Bill Himpler, American Financial Services Association, E1254 [4OC]

——— Jeffrey D. DeBoer, Real Estate Roundtable, Inc., E1230 [27SE]

——— Jim King, ScottsMiracle-Gro Co., E1253 [4OC]

——— John Smaby, National Association of Realtors, E1230 [27SE]

——— Ken A. Crerar, Council of Insurance Agents & Brokers, E1239 [1OC]

——— Lindsay Robinson, California Cannabis Industry Association, E1441 [14NO]

——— Marsha Jones, Third Party Payment Processors Association, E1229 [27SE]

——— Mayors Coalition To Push for Marijuana Reform, E1253 [4OC]

——— Michael F. Beech, Brink’s, Inc., E1240 [1OC]

——— National Association of Attorneys General, E1215 [26SE]

——— Neal Levine, Cannabis Trade Federation, E1441 [14NO]

——— Neill Franklin, Law Enforcement Action Partnership, Inc., E1228 [27SE]

——— Nicole Fried, Florida Dept. of Agriculture and Consumer Services, E1442 [14NO]

——— Paul A. Smith, Rural County Representatives of California (organization), E1239 [1OC]

——— Representatives McHenry and Luetkemeyer, Committee on Financial Services (House), H7965 [25SE]

——— Rob Nichols, American Bankers Association, E1216 [26SE]

——— Saphira Galoob, National Cannabis Roundtable (organization), E1441 [14NO]

——— Scott Talbott, Electronic Transactions Association, E1229 [27SE]

——— several bankers associations, E1216 [26SE]

——— several former Office of National Drug Control Policy and DEA officials, H7966 [25SE]

——— several organizations, E1217 [26SE]

——— several State banking supervisors, E1262 [8OC]

——— several State Governors, E1262 [8OC]

——— several trade associations, E1239 [1OC], E1254 [4OC]

——— Shanita Penny, Minority Cannabis Business Association, E1240 [1OC]

Synthetic Opioid Exposure Prevention and Training Act: Representative Bennie G. Thompson, Committee on Homeland Security (House), H9370 [9DE]

——— Representative Neal, Committee on Ways and Means (House), H9369 [9DE]

U.S.-Northern Triangle Enhanced Engagement Act: Representative Engel, Committee on Foreign Affairs (House), H5784 [15JY]

——— Representative Nadler, Committee on the Judiciary (House), H5785 [15JY]

Lists

Availability of medications in H.R. 3, Lower Drug Costs Now Act reference countries, H10099–H10101 [11DE]

Organizations and officials supporting H.R. 1595, Secure and Fair Enforcement (SAFE) Banking Act, H7971 [25SE]

Top Medicare Part B drugs not covered by Dept. of Veterans Affairs (excluding vaccines), H10099 [11DE], H10217 [12DE]

Memorandums

Medicare for All Act: Wen S. Shen, Congressional Research Service, S4750 [10JY]

Messages

Budget of the U.S. Government for Fiscal Year 2020: President Trump, S1760 [11MR], H2625 [11MR]

National Emergency Relative to Narcotics Traffickers in Colombia: President Trump, S5790 [15OC], H8137 [15OC]

Veto of H.J. Res. 46, Terminate President Trump’s Declared National Emergency To Obtain Funding for Construction of a Continuous Wall or Fence Along Southern U.S. Border: President Trump, H2750 [18MR]

Veto of S.J. Res. 54, Terminate President Trump’s Declared National Emergency To Obtain Funding for Construction of a Continuous Wall or Fence Along Southern U.S. Border: President Trump, S5838, S5852 [16OC]

Motions

Dept. of HHS: establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10044 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H10223 [12DE]

Health: reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3904 [16MY]

Notices

Estimated budget effects of H.R. 835, Anti-Doping Act, H8384 [22OC]

Estimated budget effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Estimated budget effects of H.R. 1595, Secure and Fair Enforcement (SAFE) Banking Act, H7987 [25SE]

Estimated budget effects of H.R. 1839, Medicaid Services Investment and Accountability Act, H2793 [25MR]

Estimated budget effects of H.R. 2615, U.S.-Northern Triangle Enhanced Engagement Act, H5824 [15JY]

Intention to object to H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act: Senator Braun, S1910 [14MR]

Remarks in House

Abortion: prohibit chemical abortions performed without the presence of a health care provider (H.R. 4935), H8816 [13NO], H9064 [20NO]

Advertising: require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising, H10214, H10215 [12DE]

Alliance for Substance Abuse Progress in Bartholomew County, IN: tribute, H5308 [10JY]

American Pharmacists Month: observance, H8600 [30OC]

Arkansas: tribute to Prescription for Life program, H5084 [25JN]

Armed Forces: impact on readiness of diverting funds to construction of a continuous wall or fence along southern U.S. border, H2821 [26MR]

Armstrong-Indiana-Clarion Drug and Alcohol Commission: Dept. of HHS grant to expand Addiction Recovery Mobile Outreach Team recipient, H7993 [26SE]

Boone Drug, Inc.: anniversary, H1169 [23JA], E99 [28JA]

CDC: Garrett Lee Smith Campus Suicide Prevention Grant Program funding through reductions in Dept. of HHS Substance Abuse and Mental Health Services Administration funding, H4568, H4569 [12JN]

——— National Center for Injury Prevention and Control suicide awareness, research, and prevention funding, H4613, H4614 [12JN]

——— neonatal abstinence syndrome research funding, H4579 [12JN]

——— Opioid-Related Infectious Disease program funding, H4611, H4612 [12JN]

Central America: reduce foreign assistance provided to El Salvador, Guatemala, and Honduras, H3121 [8AP]

——— support people and strengthen U.S. national security by addressing root causes of migration from El Salvador, Guatemala, and Honduras, H5576, H5580 [10JY], H7448 [25JY]

——— support people and strengthen U.S. national security by addressing root causes of migration from El Salvador, Guatemala, and Honduras (H.R. 2615), H5780–H5786 [15JY], E1026 [2AU]

——— support people and strengthen U.S. national security by addressing root causes of migration from El Salvador, Guatemala, and Honduras (H.R. 3524), H5580 [10JY]

Coast Guard: drug interdiction funding, H8061, H8064 [27SE]

Community Human Services: anniversary, E1301 [17OC]

Congress: legislative priorities, H8155 [16OC], H8708 [31OC]

Consumers: lower out of pocket spending, protect access to new cures and medications, strengthen transparency, and encourage competition, H10041 [11DE], H10133–H10139, H10201, H10202, H10204, H10209, H10211, H10215, H10216, H10219, H10235 [12DE]

——— lower out of pocket spending, protect access to new cures and medications, strengthen transparency, and encourage competition (H.R. 19), H10022, H10027, H10035, H10098–H10122 [11DE]

Crime: sanction manufacturers who provide synthetic opioids to traffickers and financial institutions that assist such entities, fund law enforcement and intelligence agencies, and establish Commission on Synthetic Opioid Trafficking, H5654 [11JY]

DEA: eliminate separate registration requirement for dispensing narcotic drugs categorized in schedules with lower potential for abuse that are intended for maintenance or detoxification treatment (H.R. 2482), H3508 [9MY], H7998 [26SE]

Democratic Party: national agenda, H8837 [14NO]

Dept. of Agriculture: improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (H.R. 5249), H9230 [4DE]

——— Rural Health and Safety Education Program funding to combat opioid epidemic in rural communities, H4942 [20JN]

Dept. of Defense: ensure cultural competence and diversity are considered in recruitment and retention efforts for mental health providers, H5659 [11JY]

——— establish partnerships with academic health centers to reduce opioid dependency, develop new pain management methods, and advance technologies to improve lives of wounded veterans, H5658 [11JY]

——— importance of counterdrug operations in transit zone and Caribbean basin, H5629 [11JY]

——— include in each national defense strategy steps to strengthen the U.S. industrial base and to assure an uninterrupted supply of medicines (H.R. 4710), E1297 [17OC]

——— provide flexibility to provide technical assistance by U.S. military women to military women in other countries combating violence as a weapon of war, terrorism, human trafficking, or narcotics trafficking, H4711–H4713 [18JN]

——— restore funding to military construction projects that had funds diverted to fund national emergency declared by President Trump in order to construct a continuous wall or fence along southern U.S. border, H7739–H7742 [17SE]

Dept. of Education: establish State-Federal partnerships to provide students with debt-free college, provide Pell Grant eligibility to certain immigrants, and restore assistance eligibility for drug-related offenses (H.R. 1571), H3397–H3399 [1MY]

Dept. of HHS: add a new set of measures to Medicare Advantage program 5-star rating system in order to encourage increased access to biosimilar biological products, H10203, H10204 [12DE]

——— address opioid drug abuse epidemic, H10032 [11DE]

——— allow Dept. of Veterans Affairs to purchase drugs at Fair Price Negotiation Program prices, H10216, H10217 [12DE]

——— authorize a pilot program to develop, expand, and enhance commercialization of biomedical products, H10204, H10205 [12DE]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments, H4639, H4640 [13JN]

——— conduct study to identify how parental substance abuse affects adoption outcomes, H3990 [20MY]

——— encourage Health Resources and Services Administration coordination with Dept. of Agriculture to improve rural health care access, H4616, H4617 [12JN]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 2062), E397 [3AP]

——— ensure Fair Price Negotiation Program and Medicare changes to reduce drug prices will not result in fewer new drug applications for unmet medical needs and life-saving cures, H10223, H10224 [12DE]

——— ensure State plans for safe care of infants exposed to substances in utero do not unfairly target pregnant women who need to remain on certain medications, H3990 [20MY]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize certain companies, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), consideration (H. Res. 758), H10033–H10042 [11DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), H7854–H7857 [20SE], H7873 [24SE], H7996 [26SE], H8153 [16OC], H8207 [17OC], H8232, H8250, H8252 [18OC], H8371, H8374 [22OC], H8397, H8398 [23OC], H8592 [29OC], H8606, H8607, H8608 [30OC], H8682 [31OC], H8775 [12NO], H8792 [13NO], H8831, H8835, H8873 [14NO], H8884, H8905, H8906 [15NO], H8963, H8966, H9052–H9054 [19NO], H9157 [21NO], H9210 [3DE], H9288–H9290 [5DE], H9955, H9956 [10DE], H10020, H10022, H10023, H10025, H10026, H10027, H10031, H10032, H10033, H10096–H10122 [11DE], H10128, H10129–H10225, H10235 [12DE]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), motion to recommit, H10223, H10224 [12DE]

——— establish grant program for States to reduce unnecessary costs and administrative burdens in health care, H10213, H10214 [12DE]

——— establish grant program to provide supportive services in permanent supportive housing for chronically homeless individuals who have physical or mental health conditions or substance use disorders (H.R. 3272), E770 [13JN]

——— incentivize low-cost drug options and generic competition and extend funding for community health centers, National Health Service Corps, teaching health centers and other public health programs (H.R. 2700), H3804 [15MY], H3856, H3857 [16MY], H4013 [21MY]

——— include coverage for Federal employee health plans in Fair Price Negotiation Program to reduce drug prices, H10215, H10216 [12DE]

——— increase maximum number of special masters allowed in U.S. Court of Federal Claims to hear cases under National Vaccine Injury Compensation Program (H.R. 3003), E665 [23MY]

——— medication-assisted treatment of opioid abuse funding, H4561 [12JN]

——— Minority HIV/AIDS Fund funding, H4621, H4622 [12JN]

——— National Survey of Child and Adolescent Well-Being funding to expand data collection to include children impacted by parental substance abuse, H4564, H4565 [12JN]

——— negotiate prices of prescription drugs furnished under Medicare part D and mandate production of generic versions of drugs if pharmaceutical companies fail to negotiate in good faith (H.R. 1046), H2947 [2AP], H3309 [30AP]

——— Office of Infectious Disease and HIV/AIDS Policy National Vaccine Program funding, H4563 [12JN]

——— prevent spread pricing in Medicaid by pharmacy benefit managers and increase funding for NIH clinical trials, H10218 [12DE]

——— report on extent to which increases in prices of commonly prescribed drugs has caused individuals with health insurance to forego needed treatment, H3885, H3886 [16MY]

——— require another Senate-confirmed officer within the Dept., to carry out drug price negotiation duties should the Sec. of HHS have a conflict of interest, H10205, H10206 [12DE]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (H.R. 2069), H8607 [30OC], H8911 [18NO]

——— require drug manufacturers to submit a transparency and justification report prior to increasing certain drug prices (H.R. 2296), H10118 [11DE]

——— require manufacturers to justify drug price spikes and high launch prices and report on drug, device, biological, and medical supply product samples provided to health care providers (H.R. 2113), H3429 [2MY]

——— require navigators to provide information in plain language regarding essential health benefits and coverage and treatment parity for mental health and substance abuse, H3890, H3891 [16MY]

——— require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements (H.R. 4640), H10140 [12DE]

——— require review and submittal of report on whether being a victim of domestic violence, dating violence, sexual assault, or stalking increases the likelihood of having a substance use disorder, H3041, H3042 [3AP]

——— research on certain Schedule I drugs that have shown promise in treating critical diseases funding, H4612, H4613 [12JN]

——— Substance Abuse and Mental Health Services Administration Building Communities of Recovery program funding, H4567, H4568 [12JN]

——— Substance Abuse and Mental Health Services Administration fentanyl test strip distribution funding, H4566 [12JN]

——— Substance Abuse and Mental Health Services Administration grants to States to develop best practices for emergency room treatment of opioid overdose patients funding, H4564 [12JN]

——— Substance Abuse and Mental Health Services Administration Regional Centers of Excellence in Substance Use Disorder Education funding, H4565 [12JN]

——— Substance Abuse Prevention and Treatment Block Grants and State Opioid Response Grants program funding, E849 [26JN]

Dept. of Homeland Security: ensure U.S. Customs and Border Protection officers, agents, and other personnel have adequate synthetic opioid detection equipment and a process to update synthetic opioid detection capability (H.R. 4761), H9367–H9369 [9DE]

——— establish joint task force to integrate border security operations to detect, interdict, disrupt, and prevent narcotics, such as fentanyl and other synthetic opioids, from entering U.S. (H.R. 3722), H8022–H8024 [26SE]

——— postpone impeachment inquiry until after operational control of the U.S. southern border has been achieved, H8555 [29OC]

——— protect U.S. Customs and Border Protection officers, agents, other personnel, and canines against potential synthetic opioid exposure (H.R. 4739), H9369, H9370 [9DE]

Dept. of HUD: provide that an individual who uses marijuana in compliance with State law may not be denied occupancy of federally assisted housing (H.R. 2338), E478 [18AP]

Dept. of Justice: Comprehensive Opioid Abuse Program funding, H4936 [20JN]

——— prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (H.R. 493), E36 [11JA]

——— prohibit funding to interfere in marijuana policy of States, District of Columbia, and U.S. territories, H4890, H4891 [19JN]

——— prohibit funding to interfere in use, distribution, possession, or cultivation of marijuana by Indian tribes, H4890 [19JN]

——— protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse position in Texas v. U.S., H5175, H5176 [26JN]

——— provide for programs to help reduce the risk that prisoners will recidivate upon release from prison, H968 [22JA]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (H.R. 2070), H3914 [16MY]

——— veterans’ treatment courts funding, H4895 [19JN], H4934 [20JN]

Dept. of the Treasury: combat money laundering, H7451 [25JY]

Dept. of Veterans Affairs: carry out a clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (H.R. 712), E78 [23JA]

——— ensure access to child care for veterans while receiving substance or drug abuse counseling at a departmental facility, H1424 [7FE]

——— furnish Vet Center counseling and mental health services to National Guard, Reserve, or Coast Guard members who participated in drug interdiction or emergency or disaster response (H.R. 1812), H4034, H4035 [21MY]

——— prohibit funding to implement, administer, or enforce policy to limit access to clinical programs for veterans participating in State-approved marijuana program, H5015 [21JN]

——— public-private partnerships to address veteran suicide prevention, post-traumatic stress disorder, traumatic brain injury, and substance abuse disorder funding, H5015 [21JN]

Depts. of HHS and Education: ensure access by students and faculty of pharmacy schools to information on use and availability of generic drugs and biosimilar biological products, H3882 [16MY]

Discount Drug Mart, Inc.: anniversary, E516 [1MY]

Diseases and disorders: facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts, H10594 [17DE]

——— facilitate effective research on, and treatment of, neglected tropical diseases through coordinated international efforts (H.R. 3460), H9194–H9197 [3DE]

Drug abuse: address fentanyl abuse, H3852 [16MY]

——— address prescription opioid and heroin abuse, H374 [10JA], H548 [15JA], H2106 [26FE], H7993, H8043 [26SE], H9259 [5DE]

——— provide for opioid use disorder prevention, recovery, and treatment, E1330 [23OC]

FDA: clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 269), H237–H266 [8JA]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 3443), E971, E977 [24JY]

——— clarify types of patents on safe and effective drug list, require list of applicable exclusivities for listed drugs, update patent sponsor requirements, and reform patent list guidelines (H.R. 1503), H3486–H3488 [8MY], H4401 [11JN]

——— funding, H392 [10JA]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application, H3800 [15MY], H3857, H3860 [16MY]

——— increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application (H.R. 938), H3429 [2MY], H10118 [11DE]

——— invest in qualified clinical testing for high-risk, high-reward drugs that address unmet medical needs to treat rare and life-threatening diseases, H10210, H10211 [12DE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market, H3858, H3864, H3865, H3873 [16MY]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (H.R. 965), H3429 [2MY], H3455 [7MY], H3911 [16MY]

——— prohibit funding to finalize, implement, or enforce draft guidance on drug products labeled as homeopathic, H4943, H4944 [20JN]

——— provide for publication of a list of licensed biological products (H.R. 1520), H3485, H3486 [8MY]

——— restrict direct-to-consumer drug advertising, H8966 [19NO]

Financial institutions: create protections for depository institutions that provide financial services to legitimate marijuana-related businesses (H.R. 1595), H7911, H7962–H7974, H7979, H7980 [25SE], E1215 [26SE], E1239 [1OC], E1253, E1256 [4OC], E1440 [14NO]

Foreign countries: impose sanctions relative to foreign traffickers of illicit opioids, H5673 [11JY]

——— impose sanctions relative to foreign traffickers of illicit opioids (H.R. 2483), H4060 [21MY]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (H.R. 2374), H3455 [7MY]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (H.R. 2376), H3455 [7MY]

GAO: conduct study on how virtual currencies and online marketplaces are used to facilitate sex and drug trafficking (H.R. 502), H1223–H1227 [28JA]

Gay, Dallas: Gainesville, GA, Rotary Club Man of the Year award recipient, E218 [27FE]

Government regulations: clarify how synthetic drugs known as analogues are to be regulated, H2618 [11MR]

Hamilton County, OH: tribute to efforts to address prescription opioid abuse, H2721 [14MR]

Health: accelerate discovery, development, and delivery of 21st century lifesaving cures and devices, E41 [14JA]

——— acknowledge impact of high cost of prescription drugs on communities of color and persons living in rural or sparsely populated areas, H10208–H10210 [12DE]

——— address high costs of health care, prescription drugs, and health insurance coverage, H4687 [13JN], H5314 [10JY], H5925 [17JY], H7166 [23JY], H8463 [28OC]

——— extend certain public health programs, H9037, H9039 [19NO]

——— extend certain public health programs (H.R. 4378), H7786–H7796, H7806 [19SE], E1190 [20SE], E1204 [24SE]

——— extend certain public health programs (H.R. 4378), consideration (H. Res. 564), H7783–H7786 [19SE]

——— protect health care of all Americans, especially those with preexisting conditions, and ensure a replacement for the Patient Protection and Affordable Care Act if it is struck down in Texas v. U.S., H3140 [9AP]

——— protect health care of all Americans, especially those with preexisting conditions, and ensure a replacement for the Patient Protection and Affordable Care Act if it is struck down in Texas v. U.S. (H. Res. 280), H3517 [9MY]

——— recognize importance of vaccinations and immunizations, H3287 [29AP]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), H3715 [10MY], H3731 [14MY], H3800 [15MY], H3851, H3852, H3853–H3911, H3913 [16MY], H4123 [23MY], H4401 [11JN], H5085 [25JN], H5175 [26JN], H7693 [12SE], H9248 [4DE], E623 [17MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), consideration (H. Res. 377), H3801–H3813 [15MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), corrections in engrossment, H3911 [16MY]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), motion to recommit, H3908, H3909 [16MY]

——— use of technology to improve services and reduce costs of health care, H2705–H2707 [13MR], H3062–H3064 [3AP], H4306–H4308 [4JN], H7828 [19SE], H8591–H8593 [29OC], H8873 [14NO], H9288–H9290 [5DE]

House of Representatives: legislative priorities, H3089 [4AP], H3240 [10AP], H3851 [16MY], H5982 [17JY], H7718 [17SE], H8377 [22OC], H8553 [29OC], H12152, H12180, H12181 [18DE]

Immigration: clarify admissibility and deportability of aliens acting in accordance with State and foreign marijuana laws (H.R. 2703), E591 [14MY]

——— impact of illegal immigration on violent crime, H1354 [5FE], H2801 [26MR]

——— secure the border between the U.S. and Mexico, H349 [9JA], H371, H392, H395, H442–H449 [10JA], H499, H513–H516 [11JA], H538–H543 [14JA], H548, H587–H597 [15JA], H989–H995 [22JA], H1002, H1152, H1155–H1157, H1166–H1169 [23JA], H1177–H1181 [24JA], H1236, H1239–H1241 [28JA], H1253, H1272, H1275, H1277, H1279 [29JA], H1321–H1325 [30JA], H1380–H1383 [6FE], H1432–H1438, H1440–H1443 [7FE], H1484 [8FE], H1507, H1508, H1509 [11FE], H1533 [13FE], H2001 [14FE], H2106 [26FE], H3092, H3094 [4AP], H3667 [9MY], H3997 [20MY], H4156 [23MY], H4298, H4308–H4310 [4JN], H5028–H5034 [21JN], H5770 [12JY]

Indian Health Service: Urban Indian Health Program funding, H4784 [19JN]

Insulin: address rising cost, H2946 [2AP], H9248 [4DE], E1030 [2AU]

Insurance: establish a public health plan (H.R. 2000), H2947 [2AP], H5313 [10JY]

——— require health plan oversight of pharmacy benefit manager services (H.R. 5304), H10204 [12DE]

International Self-Care Day: observance, E977 [24JY]

Law enforcement: develop a national strategy to combat financial networks of transnational organized criminals (H.R. 1387), H2624 [11MR]

——— stop production of fentanyl and its trafficking into the U.S. from China, H2809 [26MR]

LeMond, Greg: award Congressional Gold Medal (H.R. 3589), H7814–H7816 [19SE]

Marijuana: decriminalize, expunge prior convictions, tax products to create programs for those adversely affected by War on Drugs, and provide assistance and collect data on small businesses (H.R. 3884), H7969, H7971 [25SE]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans (H.R. 127), E7 [3JA]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (H.R. 1456), H7969, H7971 [25SE]

——— reschedule marijuana under the Controlled Substances Act, H7965, H7969, H7970 [25SE]

Medicaid: extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (H.R. 1839), H2773–H2780, H2781 [25MR], H3224 [10AP], E354 [26MR]

Medicare: allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, H7997 [26SE]

——— establish an improved Medicare for All national health insurance program (H.R. 1384), H2709–H2711 [13MR], H3309 [30AP], H4298 [4JN], H10009 [10DE]

——— negotiate prices of excessively costly life-sustaining prescription drugs (H.R. 5039), H8836 [14NO]

——— provide for a cap on beneficiary liability under part D (H.R. 4649), H8232 [18OC], H8607 [30OC]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D, H10038 [11DE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (H.R. 4661), H8207 [17OC]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D, H10135 [12DE]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (H.R. 4655), H8397 [23OC]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans, H10110 [11DE]

——— provide for intelligent assignment of certain subsidy eligible individuals auto-enrolled under prescription drug plans and Medicare Advantage prescription drug plans (H.R. 4669), H8148 [16OC]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to disclose aggregate rebates and what proportion of those rebates go to beneficiaries (H.R. 2115), H8516–H8519 [28OC], E1366 [29OC], E1383 [31OC]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation, H10134, H10201 [12DE]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D, H3658–H3661 [9MY]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (H.R. 1034), H8961 [19NO]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (H.R. 275), H2379 [6MR]

Medicare/Medicaid: eliminate cost-sharing relative to coverage of insulin as a covered part D drug under Medicare or as a covered outpatient drug under Medicaid (H.R. 366), H3311 [30AP], H3866 [16MY], H7996 [26SE]

——— provide Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information (H.R. 1781), H3800 [15MY], H8519, H8526, H8527 [28OC]

Minnesota Recovery Connection (organization): tribute, H7563 [10SE]

NAFTA: impact on drug trafficking, H278 [8JA]

National Academy of Medicine: study role of Federal funding and research in drug development, H3878 [16MY]

National Alcohol and Drug Addiction Recovery Month: observance, H7993 [26SE]

National Association of Chain Drug Stores: tribute to annual RxIMPACT Day on Capitol Hill, E223 [27FE]

National Drug Court Month: observance, H3800 [15MY]

National Opioid Awareness Week: observance, H7605 [11SE]

National Prescription Drug Take Back Day: observance, H3296 [29AP]

National Recovery Month: designate (H. Res. 586), H7869 [24SE]

——— observance, H7998, H8043 [26SE], H8074 [27SE], E1204 [24SE]

Nielsen, Sec. of Homeland Security: resignation, H3118 [8AP], E432 [9AP]

NSF: support research on opioid addiction (H.R. 3153), H7172, H7173 [23JY], E1010 [30JY]

Office of National Drug Control Policy: Drug-Free Communities Support Program funding, H5187 [26JN]

——— High Intensity Drug Trafficking Areas program funding, H5109 [25JN], H5178 [26JN]

——— make technical corrections to reauthorization (H.R. 3889), H8165–H8167 [16OC]

Office of the Director of National Intelligence: assess drug trafficking and human trafficking and smuggling in Mexico and Northern Triangle countries of El Salvador, Guatemala, and Honduras, H5889, H5890 [16JY]

Patient Protection and Affordable Care Act: impact of implementation on health care, coverage, costs, and accessibility, H9248 [4DE]

——— prohibit any guidance or rule that would reduce availability or affordability of coverage for substance use disorders, including opioid use disorders, H3540 [9MY]

——— provide opioid specific education and training for navigators and certified application counselors, H3879 [16MY]

Pennsylvania State University: tribute to Consortium To Combat Substance Abuse, H3296 [29AP]

Pharmaceuticals: implement strategy to reduce prescription drug prices, H3464 [7MY], H3658–H3661 [9MY], H7094 [18JY], H8153 [16OC], H8303 [22OC]

——— prohibit biological product manufacturers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market, H3800 [15MY], H3856 [16MY]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, H3800 [15MY], H3856 [16MY]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market (H.R. 2375), H3296 [29AP], H3455 [7MY]

PRS, Inc.: anniversary of CrisisLink suicide prevention program, E743 [11JN]

Right To Try Act: implementation, H9126 [21NO]

Rural areas: combat drug trafficking, H9230 [4DE]

Safe Kids North Carolina (organization): anniversary, E573 [10MY]

Safety: facilitate responsible, informed dispensing of controlled substances and other prescribed medications (H.R. 4810), E1330 [23OC]

Social Security: reform (H.R. 5392), H10021 [11DE]

Sports: establish criminal penalties and civil remedies for doping fraud violations at major international competitions and require sharing of information with U.S. Anti-Doping Agency (H.R. 835), H1271 [29JA], H8339–H8345 [22OC]

Stewart, Rachelle: Saline County, AR, Sheriff’s Office Lifesaving Award recipient, H9352 [9DE]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: anniversary, E1350 [28OC]

Texas: request reimbursement of costs incurred from providing additional security along the southern border, H5144 [25JN]

Trump, President: evaluation of administration, H5312 [10JY]

——— request to divert military construction funds in order to fund declared national emergency to construct a continuous wall or fence along southern U.S. border, H8061–H8071 [27SE]

——— State of the Union Message, H1367 [6FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), H2105, H2106, H2111, H2112, H2130–H2141, H2221 [26FE], H2237, H2241 [27FE], H2296–H2299 [28FE], H2750 [18MR], E193 [22FE], E228, E230 [28FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), consideration (H. Res. 144), H2112–H2119 [26FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), veto, H2801, H2804, H2806–H2812, H2821 [26MR]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), H8061–H8071 [27SE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), consideration (H. Res. 591), H7999–H8005 [26SE]

U.S. Export Finance Agency: prohibit assistance to foreign state-owned entities if the foreign governments are found not to be cooperating with U.S. to prevent synthetic opioid trafficking, H8864, H8865 [14NO]

——— prohibit transactions with individuals involved in sanctionable activities related to illegal trafficking of synthetic opioids, H8862, H8863 [14NO]

Venezuela: provide humanitarian relief, advance a constitutional and democratic solution to political crisis, address economic reconstruction, and combat public corruption, narcotics trafficking, and money laundering, H10594 [17DE]

Virginia: tribute to Skyline Drug Task Force, H3485 [8MY]

Waconia, MN: tribute to Waconia Help, Empower, and Respect Others (HERO) Coalition, H2107 [26FE]

WellSpace Health, Inc.: anniversary, E29, E34 [10JA]

Wheat Ridge, CO: Jefferson Center (organization) recipient of Golden Rotary Ethics in Business Award, E547 [7MY]

World Pharmacists’ Day: observance, H7907 [25SE]

Remarks in Senate

Advertising: require disclosure of list prices of prescription drugs and biological products in direct-to-consumer television advertising, S3809 [19JN], S4707 [9JY], S4831 [16JY]

——— require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug, S1865 [14MR], S2733 [8MY], S3177 [4JN], S6418 [6NO], S6459 [7NO], S6498 [12NO], S6521, S6522 [13NO]

Business and industry: require drug manufacturers to disclose contributions to patient advocacy organizations and other health care organizations that engage in lobbying, S5127 [29JY]

Capitol Building and Grounds: authorize use of atrium in the Philip A. Hart Senate Office Building for National Prescription Drug Take Back Day, a semiannual event for the DEA (S. Res. 359), S5853 [16OC]

——— authorize use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event (S. Res. 158), S2392 [10AP]

Central America: foreign aid funding, S1395 [14FE]

——— support people and strengthen U.S. national security by addressing root causes of migration from El Salvador, Guatemala, and Honduras, S2800 [14MY]

Chemicals: include all controlled substance analogues under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use, regardless if intended for human consumption, S6279 [30OC]

China: decision to make all forms of fentanyl a controlled substance, S2250 [4AP]

Comprehensive Addiction and Recovery Act: impact, S1664–S1666 [5MR], S2737–S2739 [8MY]

——— reauthorize and expand, S7224 [19DE]

Congress: accomplishments of the 115th Congress, S13–S17 [3JA], S2798 [14MY]

——— legislative priorities, S13–S17 [3JA]

Consumers: lower out of pocket spending, protect access to new cures and medications, strengthen transparency, and encourage competition (H.R. 19), S6959 [11DE]

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (S. 2244), S6280 [30OC]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (S. 2701), S6276 [30OC]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (S. 3148), S7236 [19DE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 3070), S7116 [17DE]

Dept. of Agriculture: provide for State and tribal regulation of hemp production, S6206 [29OC]

Dept. of Defense: prohibit diversion of funds to fund national emergency declared by President Trump in order to construct a continuous wall or fence along southern U.S. border, S5559 [18SE], S5809 [16OC], S6530, S6533 [13NO], S6703 [20NO], S6784 [2DE], S6831 [4DE]

——— prohibit reallocation of national defense funding for construction of wall or fence along southern U.S. border, S3810 [19JN]

Dept. of HHS: allow personal importation of safe and affordable drugs from approved pharmacies in Canada (S. 61), S2001 [26MR], S2868 [15MY]

——— authorize State Opioid Response Grants program and allow use of funding to address methamphetamine and cocaine abuse (S. 1925), S4173 [20JN], S5091 [25JY], S7224 [19DE]

——— establish an annual reference price for insulin products for purposes of Federal health programs (S. 2817), S6479 [7NO]

——— establish Fair Price Negotiation Program to reduce drug prices, penalize companies that refuse to negotiate, and prevent excessive price increases and establish out-of-pocket caps for Medicare (H.R. 3), S5587 [19SE], S5619 [23SE], S5636 [24SE], S5716 [26SE], S5934 [22OC], S6205 [29OC], S6271 [30OC], S6523 [13NO], S6958 [11DE], S7037 [16DE]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (S. 1987), S4569 [26JN]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse, S6279 [30OC]

——— mitigate drug shortages by prioritizing review of new drug applications, inspections, and reasons for shortages and assess national security threats associated with drug and ingredient shortages (S. 2723), S6245 [29OC]

——— require pharmacies and insurance companies to improve transparency of prescription drug costs and prohibit drug manufacturers from charging U.S. consumers more for drugs than certain foreign customers (S. 977), S4754 [10JY]

Dept. of Homeland Security: develop a comprehensive strategy to gain and maintain operational control of the international borders of the U.S., S689 [28JA]

——— improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S., S1665 [5MR], S6277 [30OC]

Dept. of Justice: assessment of mission to provide fair and impartial administration of justice for all citizens, S1305–S1307 [13FE]

——— Community Oriented Policing Services (COPS) Program Anti-Methamphetamine Program funding, S6227 [29OC]

——— protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse position in Texas v. U.S., S3035 [22MY], S3177 [4JN], S3350 [12JN], S3809 [19JN], S4708, S4712 [9JY], S4746 [10JY], S4831 [16JY], S4874 [17JY], S4960 [22JY], S6746 [21NO], S6847 [4DE], S6919 [10DE]

——— protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse position in Texas v. U.S. (S. Res. 134), S2168 [2AP], S4789, S4790 [11JY]

——— protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse position in Texas v. U.S. (S. Res. 134), unanimous-consent request, S4790 [11JY]

——— provide for programs to help reduce the risk that prisoners will recidivate upon release from prison, S1301 [13FE], S3465 [13JN]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (S. 954), S2847 [15MY]

Dept. of the Interior: establish Maya Security and Conservation Partnership Program (S. 3131), S7196 [19DE]

Dept. of Veterans Affairs: eliminate copayments for medicines relative to preventive health services (S. 1573), S6591 [14NO]

——— eliminate copayments for medicines relative to preventive health services (S. 1573), unanimous-consent request, S6591 [14NO]

Drug abuse: address methamphetamine abuse, S2737–S2739 [8MY], S3465 [13JN], S5091 [25JY]

——— address prescription opioid and heroin abuse, S1585 [28FE], S1663–S1666 [5MR], S2737–S2739 [8MY], S2918 [16MY], S3147 [3JN], S3305 [11JN], S3464 [13JN], S5089–S5091 [25JY], S5126 [29JY], S5220 [31JY], S5436 [11SE]

——— provide for opioid use disorder prevention, recovery, and treatment, S3147 [3JN], S3305 [11JN], S5028, S5033 [24JY], S5437 [11SE]

Economy: revitalize the middle class, S2848–S2850 [15MY], S5733 [26SE]

FDA: clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 269), S106 [9JA], S111 [10JA]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (S. 2740), S6915, S6918, S6921, S6944, S6945 [10DE]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (S. 2740), unanimous-consent agreement, S6900 [9DE]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic, S4883–S4885 [17JY]

——— impact of Government shutdown, S117 [10JA]

——— increase competition in generic drug market by removing barriers for a generic drug to come to market by curbing patent manipulation by brand name drug manufacturers (S. 1209), S2854–S2856 [15MY]

——— increase reporting transparency and accountability relative to user fees, S6945 [10DE]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market, S2716 [8MY], S4755 [10JY], S5158 [30JY], S6527 [13NO]

——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (S. 340), S868, S873 [5FE], S875 [6FE], S2366 [10AP], S2868, S2872 [15MY], S4753 [10JY], S5177 [30JY]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition, S5158 [30JY], S6527 [13NO]

——— require manufacturers of approved biological products to disclose and list patents, biosimilarity, and exclusivity information relative to their products and promote biosimilar competition (S. 659), S1752–S1754 [11MR], S2252 [4AP], S2872 [15MY]

——— shorten monopoly periods for prescription drugs that are subjects of sudden price hikes (S. 366), S1501 [27FE]

FDA Modernization Act: implementation, S6945 [10DE]

First Step Act: anniversary, S7135, S7140 [18DE]

Foreign aid: withhold assistance from countries that do not monitor or prosecute production or distribution of illicit fentanyl and other synthetic drugs or do not require registration of tableting and encapsulating machines, S4552, S4553 [26JN]

Foreign countries: impose sanctions relative to foreign traffickers of illicit opioids, S6532 [13NO], S7021 [12DE]

——— impose sanctions relative to foreign traffickers of illicit opioids (S. 1044), S2847 [15MY]

Foreign policy: report on congressional delegation trip to Honduras, Guatemala, and El Salvador, S1756–S1758, S1765 [11MR]

FTC: deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (S. 1224), S2868 [15MY], S4488 [25JN], S4710 [9JY], S5177 [30JY]

——— prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), S2870 [15MY], S3180 [4JN], S4488 [25JN], S4762, S4763 [10JY], S5009 [23JY], S5506 [17SE], S6217 [29OC], S6272 [30OC], S6368 [5NO], S6459 [7NO], S6497 [12NO], S6520–S6524, S6527 [13NO], S6640 [19NO], S6742 [21NO]

——— prohibit anticompetitive use of patents by drug product manufacturers (S. 1416), unanimous-consent request, S6521–S6523 [13NO], S6967, S6968 [11DE]

——— study role of intermediaries in the pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (S. 1227), S4488 [25JN], S4753 [10JY], S5177 [30JY]

Gottlieb, Scott: assessment of tenure as FDA Commissioner, S2321 [9AP]

Health: address high costs of health care, prescription drugs, and health insurance coverage, S2251 [4AP], S2755 [9MY], S5436 [11SE], S6256–S6259 [29OC], S6975 [11DE]

——— extend certain public health programs (H.R. 4378), S5586, S5609 [19SE], S5618, S5619 [23SE], S5636, S5645 [24SE], S5679 [25SE], S5713, S5715, S5722 [26SE]

——— life expectancy rates, S5733 [26SE]

——— lower health care costs by ending surprise medical bills, reducing drug prices, and improving health care transparency, public health, and exchange of health information (S. 1895), S4710 [9JY], S4752, S4755 [10JY], S4834 [16JY], S5158, S5165–S5167 [30JY], S5436 [11SE], S6527 [13NO]

——— protect health care of all Americans, especially those with preexisting conditions, and ensure a replacement for the Patient Protection and Affordable Care Act if it is struck down in Texas v. U.S., S6530, S6531 [13NO]

——— recognize importance of vaccinations and immunizations (S. Res. 165), S2455 [11AP]

——— reduce prescription drug prices, facilitate entry of generic and biosimilar products into the market, strengthen Federal exchanges, and reverse extension of short-term health plans (H.R. 987), S6934 [10DE]

Immigration: increase Federal immigration judges, allow asylum-seeking individuals to apply for asylum in their home country, and provide security assistance to Central American countries to address root causes of migration, S3638 [18JN]

——— secure the border between the U.S. and Mexico, S54, S61 [8JA], S80, S81 [9JA], S111 [10JA], S155 [11JA], S167, S169 [14JA], S190, S193–S195 [15JA], S299–S305 [18JA], S484–S497 [23JA], S541, S545, S558, S561–S567 [24JA], S1356, S1372 [14FE], S1813–S1815 [13MR], S2071 [28MR], S2164 [2AP], S2411 [11AP], S2471–S2473 [29AP], S2626–S2628 [6MY], S2760, S2765 [9MY], S2800 [14MY], S2865 [15MY], S5033 [24JY]

Insulin: address rising cost, S1639 [5MR], S4761–S4764 [10JY]

——— prohibit pharmacy benefit managers and insurers from receiving rebates for insulin products for which the manufacturer has complied with list price reduction requirements and require certain deductible waivers (S. 2199), S5158 [30JY], S6527 [13NO]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees, S4754 [10JY], S5158 [30JY], S6526 [13NO]

——— establish a public health plan (S. 981), S4713 [9JY]

Law enforcement: address trafficking of illicit fentanyl, S5090 [25JY]

——— strengthen mental health system, improve public safety, and reauthorize and improve the National Instant Criminal Background Check System, S5553 [18SE]

——— use forfeited criminal proceeds resulting from prosecution of Joaquín A. Guzmán Loera (El Chapo) or other felony drug convictions for border security measures, including a border wall (S. 25), S4798 [11JY]

Marijuana: streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (S. 2032), S4633 [27JN]

Medicaid: extend certain spousal impoverishment protections, provide State option of coordinated care for children with medically complex conditions, and prevent misclassification of drugs in drug rebate program (H.R. 1839), S2203 [2AP]

——— prevent misclassification of drugs for purposes of the drug rebate program (S. 205), S2470 [29AP], S5279 [1AU]

——— prevent spread pricing by pharmacy benefit managers, S5121 [29JY]

Medicare: allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, S3022–S3024 [22MY], S3353 [12JN], S3814 [19JN], S4491 [25JN], S4835 [16JY], S6085 [23OC], S6523 [13NO], S6689 [20NO]

——— allow the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (S. 62), S2001 [26MR], S2871 [15MY]

——— ensure equal access of beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, S4754 [10JY]

——— establish an improved Medicare for All national health insurance program, S1820 [13MR], S2297 [9AP], S2399 [11AP], S2470 [29AP], S2802 [14MY], S2987 [21MY], S3067 [23MY], S4537 [26JN], S4710 [9JY], S5215 [31JY]

——— establish an improved Medicare for All national health insurance program (H.R. 1384), S1556, S1558 [28FE], S1611 [4MR], S1720 [7MR], S1769 [12MR], S2497 [30AP], S2580 [2MY], S2895 [16MY]

——— establish an improved Medicare for All national health insurance program (S. 1129), S2499 [30AP], S2533, S2542 [1MY], S2715 [8MY], S2756 [9MY], S2863 [15MY], S3019, S3020 [22MY], S3171, S3180 [4JN], S4597 [27JN], S4749–S4751 [10JY], S4880–S4882 [17JY], S5009 [23JY], S5038 [24JY], S5436 [11SE], S5716 [26SE], S5948 [22OC], S6268, S6271 [30OC], S6347 [31OC], S6695 [20NO]

——— establish part E public health plans available to everyone (S. 1261), S2561 [1MY]

——— establish Universal Medicare Program to provide comprehensive health insurance coverage for all U.S. residents, S896 [6FE]

——— reform application process of direct and indirect remuneration fees within part D prescription drug program, S4754 [10JY]

——— require manufacturers of certain single-dose vial drugs payable under part-B to provide rebates relative to amounts of such drugs discarded (S. 551), S1864 [14MR]

——— require prescription drug plans and Medicare Advantage prescription drug plans to report potential fraud, waste, and abuse to Dept. of HHS under part D (S. 1505), S3180 [4JN]

Medicare/Medicaid: improve drug programs, protect from drastic increases in manufacturer drug prices, increase transparency of pharmacy benefit manager practices, and allow payment for certain treatments, S5121, S5126 [29JY], S5177 [30JY], S5207, S5221 [31JY], S5480 [12SE]

——— lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers (S. 2543), S5888 [17OC], S6179 [28OC], S6205 [29OC], S6268 [30OC], S6375 [5NO], S6411 [6NO], S6525–S6527 [13NO], S6897 [9DE], S7037 [16DE], S7123 [18DE]

Mental health: improve outreach and access to care, S5351 [9SE]

——— strengthen parity in access to mental health care and benefits, S2996 [21MY]

Mexico: condemn shootings of several U.S. citizens in the state of Chihuahua, S6382, S6383 [5NO]

National Alcohol and Drug Addiction Recovery Month: observance (S. Res. 379), S6177 [24OC]

National Drug Prevention Week: observance, S2803 [14MY]

National Prevention Week: observance, S2918 [16MY]

Nielsen, Sec. of Homeland Security: resignation, S2285, S2286, S2288 [8AP], S2303 [9AP]

Oasis House (organization): tribute, S1665 [5MR]

Office of National Drug Control Policy: make technical corrections to reauthorization (H.R. 3889), S6614 [14NO]

Patents: provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the Patent and Trademark Office (S. 440), S4753 [10JY]

Patient Protection and Affordable Care Act: impact of implementation on health care, coverage, costs, and accessibility, S7011 [12DE]

Pharmaceuticals: implement strategy to reduce prescription drug prices, S780 [31JA], S1458 [26FE], S1501 [27FE], S1864 [14MR], S2286 [8AP], S2470 [29AP], S2716, S2733 [8MY], S2867–S2872 [15MY], S3809 [19JN], S4488, S4491 [25JN], S4706–S4708, S4710 [9JY], S4751–S4759, S4761–S4764 [10JY], S4830, S4835 [16JY], S5009 [23JY], S5094 [25JY], S5157–S5159, S5177 [30JY], S5346–S5349 [9SE], S5480 [12SE], S5887–S5889 [17OC], S6085 [23OC], S6218 [29OC], S6309 [31OC], S6467 [7NO]

——— improve access to generic prescription drugs, S5159 [30JY], S6527 [13NO]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 64), S2001 [26MR], S6527 [13NO]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals, S4755 [10JY]

Postal Service: require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs, S1665 [5MR], S2737 [8MY], S5090 [25JY]

Senate: legislative priorities, S2799 [14MY], S3032 [22MY], S5457–S5459 [12SE], S6352 [31OC], S6582, S6590 [14NO], S6640–S6642 [19NO], S6846 [4DE], S6868 [5DE]

Senate Caucus on International Narcotics Control: Marijuana and America’s Health hearing, S5934 [22OC]

Social Security: provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under certain programs, S1888 [14MR]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: impact on communities devastated by opioid epidemic, S3147 [3JN]

——— provide funding for programs and activities (S. 2102), S5437 [11SE]

Taxation: establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (S. 425), S2868 [15MY]

——— prohibit deduction for prescription drug advertising and promotional expenses, S5126 [29JY]

——— prohibit deduction for prescription drug advertising and promotional expenses (S. 73), S5221 [31JY]

Trump, President: declaration of a national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, S1569 [28FE]

——— evaluation of administration, S841, S845 [5FE]

——— evaluation of administration relative to health care, S6317 [31OC], S6589 [14NO], S6688 [20NO]

——— Federal court ruling on request to divert military construction funds in order to fund declared national emergency to construct a continuous wall or fence along southern U.S. border, S6960 [11DE]

——— proposed declaration of a national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, S1365 [14FE]

——— request to divert military construction funds in order to fund declared national emergency to construct a continuous wall or fence along southern U.S. border, S5374, S5376–S5379 [10SE], S5455, S5463–S5467, S5471 [12SE], S5502 [17SE], S5586 [19SE], S5618 [23SE], S5645 [24SE], S5861 [17OC], S6207 [29OC], S6316 [31OC], S7087 [17DE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, S1410, S1413, S1432 [25FE], S1462–S1464 [26FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (H.J. Res. 46), S1448, S1452–S1456 [26FE], S1531–S1533 [27FE], S1610, S1612–S1614 [4MR], S1637, S1648–S1650 [5MR], S1678–S1680 [6MR], S1722–S1725 [7MR], S1750 [11MR], S1770 [12MR], S1809, S1815, S1829–S1831 [13MR], S1855, S1857–S1882 [14MR], S5374 [10SE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 10), S1600–S1602 [28FE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), S5637, S5653–S5659, S5670 [24SE], S5674–S5677, S5680, S5684 [25SE], S5715 [26SE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), unanimous-consent agreement, S5668 [24SE]

——— terminate declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border (S.J. Res. 54), veto, S5861, S5869, S5874 [17OC]

U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments, S6279 [30OC]

U.S.-Mexico-Canada Agreement (USMCA): impact on prescription drug prices, S6377 [5NO]

Venezuela: provide humanitarian relief, advance a constitutional and democratic solution to political crisis, address economic reconstruction, and combat public corruption, narcotics trafficking, and money laundering, S2417–S2419 [11AP]

World Polio Day: observance, S6152 [24OC]

Reports filed

Affordable Prescriptions for Patients Act: Committee on the Judiciary (Senate) (S. 1416), S4676 [28JN]

Anti-Doping Act: Committee on the Judiciary (House) (H.R. 835) (H. Rept. 116–251), H8386 [22OC]

Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act: Committee on Energy and Commerce (House) (H.R. 938) (H. Rept. 116–46), H3438 [2MY]

Condemn Philippines State-Sanctioned Killings as Part of the ‘‘War on Drugs,’’ Arrest of Human Rights Defenders and Journalists, and Detention of Leila De Lima: Committee on Foreign Relations (Senate) (S. Res. 142), S7112 [17DE]

Consideration of H.J. Res. 46, Terminate President Trump’s Declared National Emergency To Obtain Funding for Construction of Continuous Wall or Fence Along Southern U.S. Border: Committee on Rules (House) (H. Res. 144) (H. Rept. 116–13), H2099 [25FE]

Consideration of H.R. 3, Lower Drug Costs Now Act and H.R. 5038, Farm Workforce Modernization Act: Committee on Rules (House) (H. Res. 758) (H. Rept. 116–334), H10015 [10DE]

Consideration of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act: Committee on Rules (House) (H. Res. 377) (H. Rept. 116–61), H3787 [14MY]

Consideration of H.R. 4378, Continuing Appropriations Act, 2020, and Health Extenders Act: Committee on Rules (House) (H. Res. 564) (H. Rept. 116–212), H7834 [19SE]

Consideration of S.J. Res. 54, Terminate President Trump’s Declared National Emergency To Obtain Funding for Construction of Continuous Wall or Fence Along Southern U.S. Border: Committee on Rules (House) (H. Res. 591) (H. Rept. 116–218), H7988 [25SE]

Consideration of Senate Amendment to H.R. 3055, Continuing Appropriations and Certain Public Health Programs Extension: Committee on Rules (House) (H. Res. 708) (H. Rept. 116–297), H8957 [18NO]

Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: Committee on Energy and Commerce (House) (H.R. 965) (H. Rept. 116–55), H3726 [10MY]

——— Committee on the Judiciary (House) (H.R. 965) (H. Rept. 116–55), H3726 [10MY], H3922 [16MY]

DHS Opioid Detection Resilience Act: Committee on Homeland Security (House) (H.R. 4761) (H. Rept. 116–319), H9221 [3DE]

Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act: Committee on Science, Space, and Technology (House) (H.R. 3153) (H. Rept. 116–131), H5255 [27JN]

Joint Task Force To Combat Opioid Trafficking Act: Committee on Homeland Security (House) (H.R. 3722) (H. Rept. 116–193), H7527 [30AU]

Lower Drug Costs Now Act: Committee on Education and Labor (House) (H.R. 3) (H. Rept. 116–324), H9386 [9DE]

——— Committee on Energy and Commerce (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

——— Committee on Ways and Means (House) (H.R. 3) (H. Rept. 116–324), H9345 [6DE]

Lower Health Care Costs Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1895), S4698 [8JY]

More Efficient Tools To Realize Information for Consumers (METRIC) Act: Committee on Energy and Commerce (House) (H.R. 2296) (H. Rept. 116–215), H7900 [24SE]

Orange Book Transparency Act: Committee on Energy and Commerce (House) (H.R. 1503) (H. Rept. 116–47), H3438 [2MY]

Over-the-Counter Monograph Safety, Innovation, and Reform Act: Committee on Health, Education, Labor and Pensions (Senate) (S. 2740), S6391 [5NO]

Payment Commission Data Act: Committee on Energy and Commerce (House) (H.R. 1781) (H. Rept. 116–257), H8537 [28OC]

Prescription Drug Pricing Reduction Act: Committee on Finance (Senate) (S. 2543) (S. Rept. 116–120), S5705 [25SE]

Prescription Pricing for the People Act: Committee on the Judiciary (Senate) (S. 1227), S4676 [28JN]

Preserving Access to Cost Effective Drugs (PACED) Act: Committee on the Judiciary (Senate) (S. 440), S4676 [28JN]

Protecting Consumer Access to Generic Drugs Act: Committee on Energy and Commerce (House) (H.R. 1499) (H. Rept. 116–52), H3725 [10MY]

Purple Book Continuity Act: Committee on Energy and Commerce (House) (H.R. 1520) (H. Rept. 116–48), H3447 [3MY]

Rescinding DHS’ Waiver Authority for Border Wall Act: Committee on Homeland Security (House) (H.R. 1232) (H. Rept. 116–45), H3438 [2MY]

Secure and Fair Enforcement (SAFE) Banking Act: Committee on Financial Services (House) (H.R. 1595) (H. Rept. 116–104), H4341 [5JN]

Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act: Committee on the Judiciary (Senate) (S. 1224), S4676 [28JN]

Synthetic Opioid Exposure Prevention and Training Act: Committee on Homeland Security (House) (H.R. 4739) (H. Rept. 116–318), H9221 [3DE]

U.S. Customs and Border Protection Rural and Remote Hiring and Retention Strategy Act: Committee on Homeland Security (House) (H.R. 1598) (H. Rept. 116–22), H2914 [28MR]

Venezuela Emergency Relief, Democracy Assistance, and Development (VERDAD) Act: Committee on Foreign Relations (Senate) (S. 1025), S3164 [3JN]

Vet Center Eligibility Expansion Act: Committee on Veterans’ Affairs (House) (H.R. 1812) (H. Rept. 116–75), H4009 [20MY]

Statements

Declaration of a National Emergency Concerning the U.S. Southern Border: several former national security officials, S1410–S1413, S1432–S1434 [25FE], S1452–S1455 [26FE]

Lower Drug Costs Now Act: Executive Office of the President, H10098 [11DE]

Lower Health Care Costs Act: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S4623 [27JN]

Managing Pain During the Opioid Crisis: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S2510 [30AP]

National Recovery Month Observance: Faces & Voices of Recovery (organization), E1234 [1OC]

Secure and Fair Enforcement (SAFE) Banking Act: Global Alliance for Cannabis Commerce, E1262 [8OC]

Vaccines Saves Lives—What Is Driving Preventable Disease Outbreaks: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S2509 [30AP]

Tables

Estimated pay-as-you-go effects of H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3786 [14MY], H3921 [16MY]

Estimated pay-as-you-go effects of H.R. 1839, Medicaid Services Investment and Accountability Act, H2793 [25MR]

Top opioid distributors and manufacturers 2006 through 2012, S4884 [17JY]

Testimonies

Opioid Epidemic: Beth Tanzman, Vermont Blueprint for Health, Dept. of Vermont Health Access, S1586 [28FE]

Texts of

H. Res. 144, consideration of H.J. Res. 46, terminate President Trump’s declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, H2112 [26FE]

H. Res. 377, consideration of H.R. 5, Equality Act, H.R. 312, Mashpee Wampanoag Tribe Reservation Reaffirmation Act, and H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3801 [15MY]

H. Res. 564, consideration of H.R. 4378, Continuing Appropriations Act, 2020, and Health Extenders Act, H7783 [19SE]

H. Res. 591, consideration of S.J. Res. 54, terminate President Trump’s declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, H7999 [26SE]

H. Res. 708, consideration of H.R. 3055, continuing appropriations and certain public health programs extension, H8967 [19NO]

H. Res. 758, consideration of H.R. 3, Lower Drug Costs Now Act and H.R. 5038, Farm Workforce Modernization Act, H10033 [11DE]

H.J. Res. 46, terminate President Trump’s declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, H2130 [26FE]

H.R. 3, Lower Drug Costs Now Act, H10141–H10167 [12DE]

H.R. 502, Fight Illicit Networks and Detect (FIND) Trafficking Act, H1223 [28JA]

H.R. 835, Anti-Doping Act, H8340 [22OC]

H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, H3868–H3873 [16MY]

H.R. 1503, Orange Book Transparency Act, H3486 [8MY]

H.R. 1520, Purple Book Continuity Act, H3485 [8MY]

H.R. 1595, Secure and Fair Enforcement (SAFE) Banking Act, H7962–H7964 [25SE]

H.R. 1781, Payment Commission Data Act, H8526 [28OC]

H.R. 1812, Vet Center Eligibility Expansion Act, H4034 [21MY]

H.R. 1839, Medicaid Services Investment and Accountability Act, H2773–H2776 [25MR]

H.R. 2115, Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act, H8516 [28OC]

H.R. 2615, U.S.-Northern Triangle Enhanced Engagement Act, H5780–H5784 [15JY]

H.R. 3153, Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, H7172 [23JY]

H.R. 3460, End Neglected Tropical Diseases Act, H9194 [3DE]

H.R. 3589, Greg LeMond Congressional Gold Medal Act, H7814 [19SE]

H.R. 3722, Joint Task Force To Combat Opioid Trafficking Act, H8022 [26SE]

H.R. 3889, ONDCP Technical Corrections Act, H8165 [16OC]

H.R. 4378, Continuing Appropriations Act, 2020, and Health Extenders Act, H7786–H7791 [19SE]

H.R. 4739, Synthetic Opioid Exposure Prevention and Training Act, H9369 [9DE]

H.R. 4761, DHS Opioid Detection Resilience Act, H9367 [9DE]

S. 366, Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act, S921 [6FE]

S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act, S1439 [25FE]

S. 1044, Fentanyl Sanctions Act, S2274–S2278 [4AP]

S. 1437, Drug-Price Transparency in Communications (DTC) Act, S2791 [13MY]

S. 1488, Racehorse Doping Ban Act, S2889 [15MY]

S. 1552, Marijuana Freedom and Opportunity Act, S2971 [20MY]

S. 2103, Affordable Insulin Approvals Now Act, S4809 [11JY]

S. 2400, Expanding Cannabis Research and Information Act, S5253 [31JY]

S. 2650, Medicare Prescription Drug Savings and Choice Act, S5924 [21OC]

S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act, S6921–S6930 [10DE]

S. 3148, Stopping Overdoses of Fentanyl Analogues Act, S7212 [19DE]

S. Res. 119, support goals of World Tuberculosis Day, S1909 [14MR]

S. Res. 134, protect Patient Protection and Affordable Care Act provisions on preexisting conditions and other health coverage and reverse Dept. of Justice position in Texas v. U.S., S2192 [2AP]

S. Res. 142, condemn state-sanctioned killings in the Philippines as part of the ‘‘War on Drugs,’’ arrest of human rights defenders and journalists, and continued detention of Leila De Lima, and call for immediate release, S2278 [4AP]

S. Res. 158, use of Hart Senate Office Building atrium for DEA National Drug Take Back Day event, S2391 [10AP]

S. Res. 159, Meningitis B Awareness Day, S2439 [11AP]

S. Res. 165, recognize importance of vaccinations and immunizations, S2442 [11AP]

S. Res. 177, National Adult Hepatitis B Vaccination Awareness Day, S2524 [30AP]

S. Res. 273, support the right to affordable, quality health care, S4732 [9JY]

S. Res. 359, use of Philip A. Hart Senate Office Building atrium for DEA National Prescription Drug Take Back Day, S5851 [16OC]

S. Res. 366, support goals and ideals of Red Ribbon Week, S5926 [21OC]

S. Res. 379, National Alcohol and Drug Addiction Recovery Month, S6161 [24OC]

S. Res. 444, urge VH1 (televison network) to cancel ‘‘Cartel Crew’’ and reconsider its standards in developing shows, S6762 [21NO]

S.J. Res. 54, terminate President Trump’s declared national emergency to obtain funding for construction of a continuous wall or fence along southern U.S. border, S5759 [26SE], H8061 [27SE]